WO2020011086A1 - 苯并二氮杂环类化合物、其制备方法及用途 - Google Patents

苯并二氮杂环类化合物、其制备方法及用途 Download PDF

Info

Publication number
WO2020011086A1
WO2020011086A1 PCT/CN2019/094579 CN2019094579W WO2020011086A1 WO 2020011086 A1 WO2020011086 A1 WO 2020011086A1 CN 2019094579 W CN2019094579 W CN 2019094579W WO 2020011086 A1 WO2020011086 A1 WO 2020011086A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
alkylene
phenyl
ring
Prior art date
Application number
PCT/CN2019/094579
Other languages
English (en)
French (fr)
Inventor
刘金明
刘春池
任云
蔡家强
宋彬彬
何彦颖
王利春
王晶翼
Original Assignee
四川科伦博泰生物医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 四川科伦博泰生物医药股份有限公司 filed Critical 四川科伦博泰生物医药股份有限公司
Priority to CN201980032188.9A priority Critical patent/CN112119065B/zh
Publication of WO2020011086A1 publication Critical patent/WO2020011086A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention belongs to the field of medicine, and particularly relates to a class of benzodiazepine compounds, a preparation method and application thereof, and a pharmaceutical composition containing the compound.
  • the present invention relates to a compound of formula I, a method for its preparation, the use of a compound of formula I as a ROR ⁇ modulator for the prevention and / or treatment of diseases, and a pharmaceutical composition containing a compound of formula I.
  • Retinoic acid receptor-related orphan nuclear receptor plays a regulatory role in a variety of physiological processes, including three subtypes of ROR ⁇ , ROR ⁇ and ROR ⁇ . Recent studies have found that, compared with retinoic acid, RORs have a higher affinity for oxidized steroid derivatives and are regulated by them. RORs are widely distributed in various tissues of the body, can directly enter the nucleus to regulate the transcription of target genes, and then participate in different physiological processes, showing different tissue specificities. Among them, ROR ⁇ is expressed in various tissues, but is highly expressed in the brain, and plays an important role in cerebellar development and bone formation.
  • ROR ⁇ has a small range of action, is mainly expressed in the brain, and plays a role in the development of the retina and cerebral cortex. ROR ⁇ can be expressed in many tissues, including thymus, liver, and skeletal muscle, and plays a key role in the development of secondary lymphoid tissues.
  • ROR ⁇ 1 is expressed in a variety of tissues
  • ROR ⁇ 2 is a subtype that is specifically expressed on immune cells.
  • ROR ⁇ 2 is a key transcription factor for the differentiation and maintenance of Th17 and Tc17 effector T cells. It regulates the secretion of effector factor IL-17 by Th17 cells, and plays an important role in the differentiation of NK cells, ⁇ T cells, and iNK T cells. These cells can mediate immunity
  • the system fights cancer cells and pathogenic microorganisms such as bacteria and fungi. In the tumor microenvironment, Th17 cells and IL-17 can recruit natural killer cells and cytotoxic CD8 + T cells to attack and kill tumor cells.
  • One aspect of the present invention provides a compound of formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite thereof.
  • prodrugs where:
  • Ring A 1 is selected from phenyl and 5-10 membered heteroaryl
  • Ring A 2 is selected from phenyl, 5-6 membered heteroaryl and 3-6 membered heterocyclyl;
  • L is a covalent bond or is selected from -C (R a ) (R b )-and -C (R a ) (R b ) -C (R a ) (R b )-;
  • R 1 is selected from C 1-6 alkyl and 4-10 membered heterocyclyl; and may be optionally substituted with 0, 1, 2 or 3 independent substituents selected from the group consisting of From: Halogen, -CN, -OH, -CO 2 R 5a , -OR 6 , -S (O) 2 -R 6 , -C (O) -N (R 5a ) (R 5b ), -N (R 5a ) C (O) R 6 , -S (O) 2 -N (R 5a ) (R 5b ), -N (R 5a ) S (O) 2 R 6 , 4-10 membered heterocyclic group, 6- 10-membered aryl and 5-10-membered heteroaryl;
  • Each R 2 is independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 Haloalkoxy and -OC 3-6 cycloalkyl;
  • Each R 3 is independently selected from halogen, cyano, hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 Haloalkoxy and -S (O) 2 -R 6 ;
  • Each R 4 is independently selected from halogen, cyano, C 1-6 alkyl, and C 1-6 alkoxy;
  • R 5a and R 5b are each independently selected from hydrogen and C 1-6 alkyl
  • R 5a and R 5b together with the nitrogen atom to which they are attached form a 3-7 membered heterocyclic group
  • R 6 is selected from C 1-6 alkyl and C 3-6 cycloalkyl
  • Each R a and R b is independently selected from hydrogen and C 1-6 alkyl
  • n 0, 1, 2 or 3;
  • n 0, 1, 2 or 3;
  • p 0, 1, or 2.
  • the invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled A compound, metabolite or prodrug, wherein said compound of formula I has a structure of formula II-A or II-B,
  • Each R a and R b is independently selected from hydrogen and C 1-4 alkyl
  • Ring A 1 , ring A 2 , R 1 , R 2 , R 3 , m and n are defined as defined in Formula I.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate Compounds, N-oxides, isotope-labeled compounds, metabolites or prodrugs, wherein: R 1 is selected from C 1-4 alkyl and 4-6 membered heterocyclic groups; and may optionally be 0, 1 or 2 It is substituted by an independent substituent selected from the group consisting of halogen, -CN, -OH, -CO 2 R 5a , -OR 6 , -S (O) 2 -R 6 , -C ( O) -N (R 5a ) (R 5b ), -N (R 5a ) C (O) R 6 , -S (O) 2 -N (R 5a ) (R 5b ), -N (R 5a ) S (O) 2 R 6 , 4-6 membered heterocyclic group,
  • R 5a and R 5b are each independently selected from hydrogen and C 1-4 alkyl
  • R 5a and R 5b together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclic group
  • R 6 is selected from C 1-4 alkyl and C 3-6 cycloalkyl
  • R 1 is selected from C 1-4 alkyl, C 1-4 haloalkyl, -C 1-4 alkylene-CN, -C 1-4 alkylene-OH, -C 1-4 alkylene -C (O) OH, -C 1-4 alkylene-C (O) OC 1-4 alkyl, -C 1-4 alkylene-OC 1-4 alkyl, -C 1-4 alkyl Alkyl-OC 3-6 cycloalkyl, -C 1-4 alkylene-S (O) 2 -C 1-4 alkyl, -C 1-4 alkylene-C (O) -NH-C 1-4 alkyl, -C 1-4 alkylene-C (O) -N (C 1-4 alkyl) (C 1-4 alkyl), -C 1-4 alkylene-NH-C (O) -C 1-4 alkyl, -C 1-4 alkylene -S (O) 2 -N (C 1-4 alkyl) (C 1-4 al
  • R 1 is selected from C 1-4 alkyl, C 1-4 haloalkyl, -C 1-4 alkylene-CN, -C 1-4 alkylene-OH, -C 1-4 alkylene -C (O) OH, -C 1-4 alkylene-C (O) OC 1-4 alkyl, -C 1-4 alkylene-OC 1-4 alkyl, -C 1-4 alkyl Alkyl-OC 3-6 cycloalkyl, -C 1-4 alkylene-S (O) 2 -C 1-4 alkyl, -C 1-4 alkylene-C (O) -NH-C 1-4 alkyl, -C 1-4 alkylene-C (O) -N (C 1-4 alkyl) (C 1-4 alkyl), -C 1-4 alkylene-NH-C (O) -C 1-4 alkyl, -C 1-4 alkylene -S (O) 2 -N (C 1-4 alkyl) (C 1-4 al
  • R 1 is selected from the group consisting of -CH 3 , -CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 -CN, -CH 2 CH 2 CH 2 -CN, -CH 2 CH 2 C (CH 3 ) 2 -CN, -CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (CH 3 ) 2 -OH, -CH 2 C (O) OH, -CH 2 CH 2 C (O) OH, -CH 2 C (CH 3 ) 2 C (O) OH, -CH 2 C (O) O-CH 3 , -CH 2 CH 2 C (O) O -CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 CH 2 C (O) O -CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 CH 2
  • R 1 is selected from the group consisting of -CH 3 , -CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 -CN, -CH 2 CH 2 CH 2 -CN, -CH 2 CH 2 C (CH 3 ) 2 -CN, -CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (CH 3 ) 2 -OH, -CH 2 C (O) OH, -CH 2 CH 2 C (O) OH, -CH 2 C (CH 3 ) 2 C (O) OH, -CH 2 C (O) O-CH 3 , -CH 2 CH 2 C (O) O -CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 CH 2 C (O) O -CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 CH 2
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate thereof , N-oxide, isotope-labeled compound, metabolite, or prodrug, wherein: ring A 1 is selected from phenyl and 5-10 membered heteroaryl; preferably, ring A 1 is selected from phenyl, pyridyl, iso Oxazolyl, pyrazolyl, and imidazo [1,2-a] pyridyl; more preferably, ring A 1 is selected from phenyl and pyridyl.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate thereof , N-oxide, isotope-labeled compound, metabolite, or prodrug, wherein: R 2 is selected from halogen, cyano, hydroxyl, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-4 haloalkane Group, C 1-4 alkoxy, C 1-4 haloalkoxy and -OC 3-6 cycloalkyl; preferably, R 2 is selected from halogen, cyano, C 3-6 cycloalkyl, C 1- 4 haloalkyl and C 1-4 haloalkoxy; more preferably, R 2 is selected from fluoro, chloro, cyano, methyl, methoxy and difluoromethoxy.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate thereof , N-oxide, isotope-labeled compound, metabolite, or prodrug, wherein: Ring A 1 is selected from phenyl and 5-10 membered heteroaryl; R 2 is selected from halogen, cyano, hydroxyl, C 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, and -OC 3-6 cycloalkyl;
  • ring A 1 is selected from phenyl, pyridyl, isoxazolyl, pyrazolyl and imidazo [1,2-a] pyridyl;
  • R 2 is selected from halogen, cyano, C 3-6 cycloalkane Alkyl, C 1-4 haloalkyl and C 1-4 haloalkoxy;
  • ring A 1 is selected from phenyl and pyridyl;
  • R 2 is selected from halogen, cyano, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 1- 4- haloalkyl and C 1-4 haloalkoxy;
  • ring A 1 is selected from phenyl and pyridyl;
  • R 2 is selected from fluorine, chlorine, cyano, methyl, methoxy and difluoromethoxy.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate thereof , N-oxide, isotope-labeled compound, metabolite or prodrug, wherein: ring A 2 is selected from phenyl and 5-6 membered heteroaryl; preferably, ring A 2 is selected from phenyl, pyridyl, iso Oxazolyl and pyrazolyl; more preferably, ring A 2 is selected from phenyl, pyridyl, isoxazolyl and pyrazolyl.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate thereof , N-oxide, isotope-labeled compound, metabolite, or prodrug, wherein: R 3 is selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy and -S (O) 2 -C 1-4 alkyl;
  • the present invention provides a compound of Formula I, Formula II-A or Formula II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, Solvate, N-oxide, isotope-labeled compound, metabolite, or prodrug, wherein: ring A 2 is selected from phenyl and 5-6 membered heteroaryl; R 3 is selected from halogen, cyano, C 1- 4- alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, and -S (O) 2 -C 1-4 alkyl;
  • ring A 2 is selected from phenyl, pyridyl, isoxazolyl and pyrazolyl;
  • R 3 is selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 Haloalkoxy and -S (O) 2 -C 1-4 alkyl.
  • ring A 2 is selected from phenyl, pyridyl, isoxazolyl and pyrazolyl;
  • R 3 is selected from trifluoromethyl, methyl, cyano, fluorine and methanesulfonyl.
  • the invention provides a compound of Formula II-A or II-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxidation , Isotope-labeled compound, metabolite, or prodrug, where:
  • Ring A 1 is selected from phenyl, pyridyl, isoxazolyl, pyrazolyl, and imidazo [1,2-a] pyridyl;
  • Ring A 2 is selected from phenyl, pyridyl, isoxazolyl and pyrazolyl;
  • R a and R b are both hydrogen
  • R 1 is selected from -CH 3 , -CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 -CN, -CH 2 CH 2 CH 2 -CN,- CH 2 CH 2 C (CH 3 ) 2 -CN, -CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (CH 3 ) 2 -OH, -CH 2 C (O) OH, -CH 2 CH 2 C (O) OH, -CH 2 C (CH 3 ) 2 C (O) OH, -CH 2 C (O) O-CH 3 , -CH 2 CH 2 C (O) O-CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 C (CH 3 ) 2 C (O) O-CH 3 , -CH 2 CH 2 -O
  • Each R 2 is independently selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy;
  • Each R 3 is independently selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, and -S (O) 2 -C 1-4 alkyl;
  • n 0, 1, 2 or 3;
  • n 0, 1, 2 or 3.
  • Another aspect of the present invention provides a compound of formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolism Substances or prodrugs, of which:
  • Ring A 1 is selected from phenyl and 5-10 membered heteroaryl
  • Ring A 2 is selected from phenyl, 5-6 membered heteroaryl and 3-6 membered heterocyclyl;
  • L is a covalent bond or is selected from -C (R a ) (R b )-and -C (R a ) (R b ) -C (R a ) (R b )-;
  • R 1 is selected from -C 1-6 alkyl; and may be optionally substituted with 0, 1, 2 or 3 independent substituents selected from the group consisting of: halogen, -CN, -OH, -CO 2 R 5a , -OR 6 , -S (O) 2 -R 6 , -C (O) -N (R 5a ) (R 5b ), -N (R 5a ) C (O) R 6 , -S (O) 2 -N (R 5a ) (R 5b ), -N (R 5a ) S (O) 2 R 6 , 6-10 membered aryl group and 5-10 membered heteroaryl group;
  • Each R 2 is independently selected from halogen, cyano, hydroxy, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 Haloalkoxy and -OC 3-6 cycloalkyl;
  • Each R 3 is independently selected from halogen, cyano, hydroxyl, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 Haloalkoxy and -S (O) 2 -R 6 ;
  • Each R 4 is independently selected from halogen, cyano, C 1-6 alkyl, and C 1-6 alkoxy;
  • R 5a and R 5b are each independently selected from hydrogen and C 1-6 alkyl
  • R 5a and R 5b together with the nitrogen atom to which they are attached form a 3-7 membered heterocyclic group
  • R 6 is selected from C 1-6 alkyl and C 3-6 cycloalkyl
  • Each R a and R b is independently selected from hydrogen and C 1-6 alkyl
  • n 0, 1, 2 or 3;
  • n 0, 1, 2 or 3;
  • p 0, 1, or 2.
  • the invention provides a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled A compound, metabolite or prodrug, wherein said compound of formula I has a structure of formula II-A or II'-B,
  • Each R a and R b is independently selected from hydrogen and C 1-4 alkyl
  • Ring A 1 , ring A 2 , R 1 , R 2 , R 3 , m and n are defined as defined in Formula I.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II'-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvent Compound, N-oxide, isotope-labeled compound, metabolite, or prodrug, wherein: R 1 is selected from -C 1-4 alkyl; and may be optionally selected from 0, 1 or 2 independently selected from Substituted by a group of substituents including: halogen, -CN, -OH, -CO 2 R 5a , -OR 6 , -S (O) 2 -R 6 , -C (O) -N (R 5a ) (R 5b ), -N (R 5a ) C (O) R 6 , -S (O) 2 -N (R 5a ) (R 5b ), -N (R 5a ) S (O) 2 R 6 , 6-10 membered aryl and 5-10 membered hetero
  • R 5a and R 5b are each independently selected from hydrogen and C 1-4 alkyl
  • R 5a and R 5b together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclic group
  • R 6 is selected from C 1-4 alkyl and C 3-6 cycloalkyl
  • R 1 is selected from -C 1-4 alkyl, -C 1-4 haloalkyl, -C 1-4 alkylene-CN, -C 1-4 alkylene-OH, -C 1-4 Alkylene-C (O) OH, -C 1-4 alkylene-C (O) OC 1-4 alkyl, -C 1-4 alkylene-OC 1-4 alkyl, -C 1- 4 alkylene-OC 3-6 cycloalkyl, -C 1-4 alkylene-S (O) 2 -C 1-4 alkyl, -C 1-4 alkylene-C (O) -NH -C 1-4 alkyl, -C 1-4 alkylene-C (O) -N (C 1-4 alkyl) (C 1-4 alkyl), -C 1-4 alkylene-NH -C (O) -C 1-4 alkyl, -C 1-4 alkylene-S (O) 2 -N (C 1-4 alkyl) (C 1-4
  • R 1 is selected from the group consisting of -CH 3 , -CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 CH 2 -CN, -CH 2 CH 2 C (CH 3 ) 2 -CN, -CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (O) OH, -CH 2 CH 2 C (O) O-CH 3 , -CH 2 CH-O-CH 3 , -CH 2 CH 2 -S (O) 2 -CH 3 , -CH 2 CH 2 -C (O) -NH-CH 3 , -CH 2 CH 2 CH 2 -C (O) -N (CH 3 ) 2 , -CH 2 CH 2 -C (O) -N (CH 3 ) 2 , -CH 2 -C (O) -N (CH 3 ) 2
  • the present invention provides a compound of Formula I, Formula II-A or Formula II'-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate Compounds, N-oxides, isotope-labeled compounds, metabolites or prodrugs, wherein: Ring A 1 is selected from phenyl and 5-10 membered heteroaryl; R 2 is selected from halogen, cyano, hydroxyl, C 1- 4 alkyl, C 3-6 cycloalkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, and -OC 3-6 cycloalkyl;
  • ring A 1 is selected from phenyl, pyridyl, isoxazolyl, pyrazolyl and imidazo [1,2-a] pyridyl;
  • R 2 is selected from halogen, cyano, C 3-6 cycloalkane C 1-4 haloalkyl, and C 1-4 haloalkoxy;
  • ring A 1 is selected from phenyl and pyridyl;
  • R 2 is selected from halogen, cyano, C 3-6 cycloalkyl, C 1-4 haloalkyl, and C 1-4 haloalkoxy;
  • R 2 is selected from fluorine, cyano, methyl, methoxy and difluoromethoxy.
  • the present invention provides a compound of Formula I, Formula II-A or Formula II'-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate Compounds, N-oxides, isotope-labeled compounds, metabolites or prodrugs, wherein: ring A 2 is selected from phenyl and 5-6 membered heteroaryl; R 3 is selected from halogen, cyano, C 1-4 alkane Group, C 1-4 haloalkyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, and -S (O) 2 -C 1-4 alkyl;
  • ring A 2 is selected from phenyl, pyridyl, isoxazolyl, and pyrazolyl;
  • R 3 is selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 Haloalkoxy.
  • R 3 is selected from trifluoromethyl, methyl, cyano, fluorine and methanesulfonyl.
  • the invention provides a compound of Formula II-A or II'-B or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, N- Oxides, isotopically labeled compounds, metabolites, or prodrugs, where:
  • Ring A 1 is selected from phenyl, pyridyl, isoxazolyl, pyrazolyl, and imidazo [1,2-a] pyridyl;
  • Ring A 2 is selected from phenyl, pyridyl, isoxazolyl and pyrazolyl;
  • R a and R b are both hydrogen
  • R 1 is selected from -CH 3 , -CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 F, -CH 2 CH 2 CH 2 -CN, -CH 2 CH 2 C (CH 3 ) 2 -CN, -CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (CH 3 ) 2 -OH, -CH 2 CH 2 C (O) OH, -CH 2 CH 2 C (O ) O-CH 3 , -CH 2 CH-O-CH 3 , -CH 2 CH 2 -S (O) 2 -CH 3 , -CH 2 CH 2 -C (O) -NH-CH 3 , -CH 2 CH 2 CH 2 -C (O) -N (CH 3 ) 2 , -CH 2 CH 2 -C (O) -N (CH 3 ) 2 , -CH 2 CH 2 -NH-C (O) -CH 3 , -CH 2
  • Each R 2 is independently selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy;
  • Each R 3 is independently selected from halogen, cyano, C 1-4 alkyl, C 1-4 haloalkyl, and -S (O) 2 -C 1-4 alkyl;
  • n 0, 1, 2 or 3;
  • n 0, 1, 2 or 3.
  • the invention provides a compound selected from:
  • the atoms in the compounds according to the invention may be replaced by their isotopes.
  • 12 C can be replaced by its isotope 13 C or 14 C; 1 H can be replaced by 2 H (D, deuterium) or 3 H (T, tritium).
  • the present invention includes compounds of Formula I, Formula II-A, Formula II-B or Formula II'-B and any atom in a compound of Formula I, Formula II-A, Formula II-B or Formula II'-B via its isotope Isotope-labeled compounds obtained after replacement.
  • the compound of formula I, formula II-A, formula II-B or formula II'-B or a pharmaceutically acceptable salt thereof, stereoisomers, tautomers, polycrystals as defined above Types, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs are also referred to as compounds of the invention.
  • the invention also relates to a method for preparing a compound of formula II-A, said method comprising the steps of:
  • X represents a leaving group, and the leaving group includes, but is not limited to, a halogen atom, a methanesulfonyloxy group, a p-methylbenzenesulfonyloxy group, and the like.
  • R 1, R 2, R 3 , R a, R b, ring A 1, ring A 2, m, n are as defined for formula II-A compounds;
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from tetrahydrofuran, N, N-dimethylformamide, N, N-dimethylacetamide, 1,4-dioxane, and any combination thereof, and tetrahydrofuran is preferred.
  • the reaction is preferably performed in the presence of a suitable condensing agent.
  • the condensing agent may be selected from the group consisting of dicyclohexylcarbodiimide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, HATU, benzotriazole-N, N, N ', N'-tetramethylurea hexafluorophosphate, 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate, HATU is preferred.
  • the reaction is preferably carried out in the presence of a suitable organic base.
  • the organic base may be selected from triethylamine, pyridine, 4-dimethylaminopyridine, diisopropylethylamine, and preferably diisopropylethylamine.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 20-50 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from an alcoholic protic solvent, N, N-dimethylformamide, N, N-dimethylacetamide, 1,4-dioxane, acetonitrile, and any combination thereof.
  • the reaction is preferably performed in the presence of a suitable base.
  • the base may be selected from sodium hydroxide, lithium hydroxide, potassium hydroxide, sodium methoxide, sodium tert-butoxide, and preferably sodium hydroxide.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 25-80 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the compound when Compound IN-A-5 in R a and R b are each methyl, the compound may be IN-A-3 with 2-methoxypropene ring closure reaction to give Compound IN-A- 5.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from acetone, acetonitrile, propionitrile, tetrahydrofuran, 1,4-dioxane, and any combination thereof, and acetonitrile is preferred.
  • the reaction is preferably performed in the presence of a suitable acid.
  • the acid may be selected from p-toluenesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, hydrochloric acid, and sulfuric acid, preferably p-toluenesulfonic acid.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 25-80 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from N, N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably A mixed solvent of toluene, ethanol, and water.
  • the reaction is preferably performed in the presence of a suitable condensing agent.
  • the catalyst may be selected from various palladium catalysts, preferably tetrakis (triphenylphosphine) palladium.
  • the reaction is preferably carried out in the presence of a suitable base.
  • the base may be selected from potassium phosphate, potassium acetate, sodium bicarbonate, sodium carbonate, potassium carbonate, and the like, and sodium carbonate is preferred.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 60-120 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from triethylamine, N, N-diisopropylethylamine, pyridine and any combination thereof, preferably pyridine.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 40-80 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the invention also relates to a method for preparing a compound of formula II-B, which method comprises the following steps:
  • X represents a leaving group, and the leaving group includes, but is not limited to, a halogen atom, a methanesulfonyloxy group, a p-methylbenzenesulfonyloxy group, and the like.
  • R 1, R 2, R 3 , R a, R b, ring A 1, ring A 2, m, n are as defined for formula II-B compound;
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from acidic solvents such as formic acid and glacial acetic acid, and any combination thereof, and is preferably glacial acetic acid.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 80-150 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from inert solvents such as diethyl ether, tetrahydrofuran, ethylene glycol dimethyl ether, and any combination thereof, and tetrahydrofuran is preferred.
  • the reaction is preferably performed in the presence of a suitable reducing reagent.
  • the reducing agent may be selected from lithium tetrahydroaluminum, borane, red aluminum, and the like, and lithium tetrahydroaluminum is preferred.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 20-50 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from triethylamine, N, N-diisopropylethylamine, pyridine and any combination thereof, preferably pyridine.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 40-80 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from N, N-dimethylformamide, N-methylpyrrolidone, toluene, ethanol, ethylene glycol dimethyl ether, water, 1,4-dioxane, and any combination thereof, preferably A mixed solvent of toluene, ethanol, and water.
  • the reaction is preferably performed in the presence of a suitable condensing agent.
  • the catalyst may be selected from various palladium catalysts, preferably tetrakis (triphenylphosphine) palladium.
  • the reaction is preferably performed in the presence of a suitable base.
  • the base may be selected from potassium phosphate, potassium acetate, sodium bicarbonate, sodium carbonate, potassium carbonate, and the like, and sodium carbonate is preferred.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 60-120 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the reaction is preferably performed in a suitable organic solvent.
  • the organic solvent may be selected from N, N-dimethylformamide, N-methylpyrrolidone, tetrahydrofuran and the like, and any combination thereof, and N, N-dimethylformamide is preferred.
  • the reaction is preferably performed in the presence of a suitable base.
  • the base may be selected from sodium hydride, potassium tert-butoxide, sodium tert-butoxide, sodium methoxide, and the like, and potassium tert-butoxide is preferred.
  • the reaction is preferably performed at a suitable temperature, and the temperature is preferably 10-40 ° C.
  • the reaction is preferably performed for a suitable time, such as 2-8 hours.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention, and optionally, one or more pharmaceutically acceptable carriers or excipients.
  • the invention also relates to a pharmaceutical formulation comprising a compound of the invention, or a pharmaceutical composition thereof.
  • the present invention also relates to the use of a compound of the present invention, a pharmaceutical composition thereof, or a pharmaceutical preparation thereof in the manufacture of a medicament as a retinoid receptor-associated orphan nuclear receptor gamma (ROR ⁇ ) modulator.
  • a compound of the present invention a pharmaceutical composition thereof, or a pharmaceutical preparation thereof in the manufacture of a medicament as a retinoid receptor-associated orphan nuclear receptor gamma (ROR ⁇ ) modulator.
  • ROR ⁇ retinoid receptor-associated orphan nuclear receptor gamma
  • the invention also relates to the use of a compound of the invention or a pharmaceutical composition thereof, or a pharmaceutical preparation thereof for the manufacture of a medicament for the prevention and / or treatment of a ROR ⁇ mediated disease or disorder.
  • the medicament further comprises other antitumor agents.
  • the present invention also relates to a method of preventing and / or treating a ROR ⁇ -mediated disease or disorder, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention, a pharmaceutical composition thereof, or a pharmaceutical preparation thereof.
  • the invention also relates to a compound of the invention, a pharmaceutical composition thereof, or a pharmaceutical formulation thereof for use in the prevention and / or treatment of a ROR ⁇ -mediated disease or disorder.
  • the present invention also relates to a compound of the present invention, a pharmaceutical composition thereof, or a pharmaceutical preparation thereof for use in modulating retinoic acid receptor-associated orphan nuclear receptor ⁇ (ROR ⁇ ).
  • ROR ⁇ retinoic acid receptor-associated orphan nuclear receptor ⁇
  • the ROR ⁇ -mediated disease or disorder is selected from a tumor or cancer, such as non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, synovial sarcoma, breast cancer, cervical Cancer, colon cancer, lung cancer, oral cancer, brain cancer, stomach cancer, liver cancer, rectal cancer, pancreatic cancer, skin cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, fallopian tube tumor, peritoneal tumor, melanoma, Solid tumor, glioma, glioblastoma, mastoid malignant tumor, head and neck tumor, leukemia, lymphoma or myeloma.
  • a tumor or cancer such as non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, synovial sarcoma, breast cancer, cervical Cancer, colon cancer, lung cancer, oral cancer, brain cancer, stomach cancer, liver cancer, rectal
  • the purpose of preparing the active ingredient into a pharmaceutical composition is to facilitate or facilitate the administration of the organism, and to facilitate the absorption of the active ingredient and thereby exert the biological activity.
  • the excipient refers to an additive other than the main drug in a pharmaceutical preparation. It is stable in nature, has no contraindications to the main drug, does not cause side effects, does not affect the efficacy, and is not easy to deform, chapped, moldy, moth-eaten, harmless to the human body, has no physiological effect, and does not produce chemical or physical properties Effect, does not affect the content of the main drug.
  • the compounds of the invention can be administered parenterally, topically, intravenously, orally, subcutaneously, intraarterially, intradermally, transdermally, rectally, intracranially, intraperitoneally, intranasally, intramuscularly or as inhalation Agent.
  • the compounds of the invention may optionally be administered in combination with other active ingredients which have at least some effect in the treatment of the various diseases described in the invention.
  • the compound of the present invention can be formulated into various suitable dosage forms according to the route of administration.
  • the pharmaceutical composition or a suitable dosage form according to the present invention may contain 0.01 to 1000 mg of a compound of the present invention.
  • the compounds of the invention can be formulated into any orally acceptable formulation, including but not limited to tablets, capsules, aqueous solutions or aqueous suspensions.
  • the compounds of the invention When applied topically to the skin, the compounds of the invention may be formulated in the form of a suitable ointment, lotion or cream formulation in which the active ingredient is suspended or dissolved in one or more carriers.
  • the compounds of the invention can also be administered in the form of sterile injectable preparations, including sterile injectable water or oil suspensions or sterile injectable solutions.
  • suitable in vitro or in vivo assays are performed to determine the effect of the pharmaceutical composition of the invention and whether the administration is suitable for treating a disease or medical disease state in an individual. Examples of these assays are described below in connection with specific diseases or medical treatments in the non-limiting examples.
  • an effective amount of a composition of the invention sufficient to achieve a prophylactic or therapeutic effect is from about 0.001 mg / kg body weight / day to about 10,000 mg / kg body weight / day.
  • the dose and frequency will vary depending on the half-life of the formulation in the subject. It can also differ depending on whether it is a preventive treatment or a therapeutic treatment.
  • relatively low doses are administered chronically at relatively low frequency intervals.
  • hydrogen as used in the present invention and hydrogen in each group refers to tritium (H), deuterium (D) or tritium (T).
  • halogen as used herein means fluorine, chlorine, bromine or iodine.
  • covalent bond used in the present invention means that two atoms use their outer electrons together and ideally reach a state of electron saturation, thereby forming a relatively stable chemical structure. Based on the valence bond theory, a covalent bond in L of formula (I) refers to a single bond formed by sharing a pair of electrons between two adjacent N atoms of L.
  • C 1-6 alkyl refers to a straight or branched chain alkyl group having 1-6 carbon atoms, such as C 1-4 alkyl, C 1-2 alkyl, C 1 alkyl, C 2 alkyl, C 3 alkyl, C 4 alkyl, C 5 alkyl or C 6 alkyl. Specific examples include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • C 1-6 haloalkyl used in the present invention refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms substituted with one or more halogen atoms, such as C 1-4 haloalkyl, C 1- 2 haloalkyl -alkyl, C 1 haloalkyl, C 2 haloalkyl, C 3 haloalkyl, C 4 haloalkyl, C 5 or C 6 haloalkyl haloalkyl.
  • Specific examples include, but are not limited to, trifluoromethyl, difluoromethyl, trifluoroethyl, monofluoromethyl and the like.
  • C 1-6 alkoxy refers to a C 1-6 alkyl-O- group, wherein C 1-6 alkyl has the meaning defined above.
  • C 1-6 haloalkoxy refers to a C 1-6 haloalkyl-O- group, wherein C 1-6 haloalkyl has the meaning defined above.
  • C 1-6 alkylene used in the present invention refers to a straight or branched chain divalent alkyl group formed by removing a hydrogen from a C 1-6 alkyl group as defined herein, such as a C 1-4 alkylene group, C 1-2 alkylene, C 1 alkylene, C 2 alkylene, C 3 alkylene, C 4 alkylene, C 5 alkylene, or C 6 alkylene.
  • Specific examples include, but are not limited to, -CH 2- , -CH (CH 3 )-, -CH 2 CH 2- , -CH 2 CH (CH 3 )-, -CH (CH 3 ) CH 2- , -CH 2 CH 2 CH 2- , -CH 2 CH 2 CH 2 CH 2- , -CH 2 C (CH 3 ) 2- , -CH 2 CH 2 CH 2 CH 2- , -CH 2 CH 2 CH 2 CH ( CH 3 )-, -CH 2 CH 2 C (CH 3 ) 2- , -CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -and so on.
  • C 3-6 cycloalkyl refers to a saturated or partially saturated monocyclic alkyl group containing 3 to 6 carbon atoms, such as a 3-, 4-, 5- or 6-membered cycloalkyl. Specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
  • 6- to 10-membered aryl group refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 10 carbon atoms in the ring portion, such as a phenyl group.
  • the term "5- to 10-membered heteroaryl” used in the present invention refers to a monocyclic or polycyclic aromatic group containing 5 to 10 ring members, and at least 1 to 4 of the ring members (for example, 1, 2 , 3 or 4) is a heteroatom selected from N, O and S.
  • the term "5- to 6-membered heteroaryl” used in the present invention refers to a monocyclic aromatic group containing 5 to 6 ring members, and at least 1 to 4 of the ring members (for example, 1, 2, 3, or 4) are heteroatoms selected from N, O, and S, such as 5-membered heteroaryl, 6-membered heteroaryl, and the like.
  • heteroaryl examples include, but are not limited to, furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1, 2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl , 1,3,4-oxadiazolyl, pyridyl, 2-pyridone, 4-pyridone, pyrimidinyl, 2H-1,2-oxazinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 4H-1,4-oxazinyl, pyridazinyl, pyrazinyl,
  • a heterocyclyl is a 4- to 6-membered heterocyclic group containing 1 or 2 members selected from N, O, and S, such as
  • substituent may be (1) unsubstituted or (2) substituted. If the carbon of a substituent is described as being optionally substituted with one or more from a list of substituents, one or more hydrogens (to the extent of any hydrogen present) on the carbon may be independently and / or together independently Selected optional substituent substitutions. If the nitrogen of a substituent is described as being optionally substituted with one or more from the list of substituents, one or more hydrogens (to the extent of any hydrogen present) on the nitrogen can each be independently selected as an optional Substitution.
  • the substituents include, but are not limited to, halogen, cyano, hydroxy, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkane Oxy, -OC 3-6 cycloalkyl, aryl such as phenyl, 5-6 membered heteroaryl, 5-6 heterocyclyl, and the like.
  • one or more means one or more than one under reasonable conditions, such as two, three, four, five or ten.
  • the point of attachment of a substituent may be from any suitable position of the substituent.
  • stereoisomer as used herein means an isomer formed due to at least one asymmetric center. In compounds having one or more (e.g. 1, 2, 3, or 4) asymmetric centers, it can produce racemic mixtures, single enantiomers, diastereomeric mixtures, and Individual diastereomers. Certain individual molecules may also exist as geometric isomers (cis / trans).
  • the compounds of the invention may exist as a mixture of two or more structurally different forms (often referred to as tautomers) in rapid equilibrium.
  • Representative examples of tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers Wait. It is to be understood that the scope of this application covers all such in any proportion (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99 %) Isomers or mixtures thereof.
  • the compounds of the invention are intended to be stereoisomers (which include cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, Geometric isomers, rotational isomers, conformers, atropisomers and mixtures thereof).
  • the compounds of the invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).
  • the invention encompasses all possible crystalline forms or polymorphs of the compounds of the invention, which may be a single polymorph or a mixture of any proportion of more than one polymorph.
  • the compound of the present invention may exist in the form of a solvate such as a hydrate, wherein the compound of the present invention contains a polar solvent as a structural element of the crystal lattice of the compound, particularly, for example, water, methanol or ethanol.
  • a polar solvent as a structural element of the crystal lattice of the compound, particularly, for example, water, methanol or ethanol.
  • the amount of polar solvents, especially water may be present in a stoichiometric or non-stoichiometric ratio.
  • the compound of the present invention or a pharmaceutically acceptable salt thereof may also form a solvate, such as an alcoholate and the like.
  • the compounds of the present invention may also be in the form of a prodrug or in the form that the active ingredient may be released after metabolic changes in the body.
  • a prodrug refers to a chemically modified active or inactive compound that, after administration to a subject, undergoes physiological actions in the body (eg, hydrolysis, metabolization, etc.) to become a compound of the invention.
  • physiological actions in the body eg, hydrolysis, metabolization, etc.
  • the compounds of the present invention may also be in the form of chemical protection, the protecting group may be protected on the active group (such as amino group) of the compound, and the protecting group may be metabolized in vivo to release the active ingredient.
  • the selection and preparation of appropriate forms of chemical protection is well known to those skilled in the art.
  • pharmaceutically acceptable means that the substance or composition must be chemically and / or toxicologically compatible with the other components making up the formulation and / or the subject treated with it.
  • pharmaceutically acceptable salt includes conventional salts formed with pharmaceutically acceptable inorganic or organic acids, or inorganic or organic bases.
  • exemplary acid addition salts include, for example, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodate, sulfate, nitrate, phosphate (e.g., for example, phosphate, hydrogen phosphate, or phosphoric acid) Dihydrogen salt), carbonate, bicarbonate or perchlorate; organic acid salts such as acetate, propionate, butyrate, valerate, hexanoate, heptanoate, caprylate, Cyclopentanepropionate, undecanoate, lactate, malate, oxalate, fumarate, tartrate, maleate, citrate, nicotinate, benzoate, Salicylate or ascorbate; sulfonates such as mesylate, ethanesulfonate, 2-hydroxyethanes
  • an effective amount refers to an amount sufficient to achieve a desired therapeutic effect, for example, an amount that achieves a reduction in symptoms associated with the disease to be treated.
  • treatment is intended to reduce or eliminate the disease state or disorder being targeted. If a subject receives a therapeutic amount of a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof according to the methods described herein, the subject exhibits one or more of the signs and symptoms Observable and / or detectable reductions or improvements, then the subject is successfully "treated”. It should also be understood that the treatment of the disease state or disorder includes not only complete treatment but also incomplete treatment, but achieves some biological or medical related results.
  • subject refers to an animal, such as a mammal. Subjects also refer to, for example, primates (eg, humans), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like.
  • primates eg, humans
  • cattle, sheep, goats horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like.
  • the structures of the compounds described in the following examples were confirmed by 1 H-NMR or MS.
  • the 1 H-NMR measurement instrument used a Bruker 400MHz nuclear magnetic resonance instrument.
  • the measurement solvent was CD 3 OD, CDCl 3 or DMSO-d 6 , and the internal standard substance was TMS. All ⁇ values were expressed in ppm.
  • the mass spectrometer (MS) was measured using an Agilent (ESI) mass spectrometer model Agilent 6120B.
  • a thin-layer chromatography silica gel plate uses an aluminum plate (20 ⁇ 20cm) manufactured by Merck.
  • the thin-layer chromatography uses GF254 (0.4-0.5mm) for separation and purification.
  • the reaction is monitored by thin layer chromatography (TLC) or LC-MS.
  • TLC thin layer chromatography
  • the developing systems used are: dichloromethane and methanol system, n-hexane and ethyl acetate system, petroleum ether and ethyl acetate system, and the volume ratio of solvent Adjust according to the polarity of the compound, or add triethylamine.
  • Column chromatography generally uses 200-300 mesh silica gel as a carrier.
  • the eluent system includes: dichloromethane and methanol systems, petroleum ether and ethyl acetate systems.
  • the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine can also be adjusted.
  • reaction temperatures in the examples are room temperature (20 ° C to 30 ° C).
  • the reagents used in the present invention were purchased from Acros Organics, Aldrich Chemical Company, Shanghai Tebo Chemical Technology Co., Ltd. and the like.
  • Example 1 3- (7- (3- (difluoromethoxy) -5-fluorophenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) Of 1,2-Dihydroquinazoline-3 (4H) -yl) propionic acid methyl ester (Compound 1)
  • Step 1 Preparation of methyl 3- (2-amino-4-bromophenylformylamino) propanoate
  • Step 5 3- (7- (3- (difluoromethoxy) -5-fluorophenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) Of 1,2-Dihydroquinazoline-3 (4H) -yl) propionic acid methyl ester (Compound 1)
  • Step 4 8- (3- (difluoromethoxy) -5-fluorophenyl) -1-((3- (trifluoromethyl) phenyl) sulfonyl) -3,4-dihydro- 1H-benzo [e] [1,4] diaza -5 (2H) -one
  • Step 5 3- (8- (3- (difluoromethoxy) -5-fluorophenyl) -5-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) -2,3-dihydro-1H-benzo [e] [1,4] diaza -4 (5H) -Methyl) propionate (Compound 3)
  • the reaction solution was poured into water (100 mL), extracted with ethyl acetate three times, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
  • the concentrate was purified by preparative high performance liquid chromatography to obtain the title compound (42.0 mg , Yield: 51.6%).
  • Step 4 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (2-methoxyethyl) -1-((3- (trifluoromethyl) phenyl ) Sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 5)
  • Example 8 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (3-methoxypropyl) -1-((3- (trifluoromethyl) phenyl ) Sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 8)
  • Example 12 7- (3- (difluoromethoxy) -5-fluorophenyl) -3-methyl-1-((3- (trifluoromethyl) phenyl) sulfonyl) -2, Preparation of 3-dihydroquinazoline-4 (1H) -one (Compound 12)
  • Example 13 7- (3- (difluoromethoxy) -5-fluorophenyl) -3-ethyl-1-((3- (trifluoromethyl) phenyl) sulfonyl) -2, Preparation of 3-dihydroquinazoline-4 (1H) -one (compound 13)
  • Example 16 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (2- (methylsulfonyl) ethyl) -1-((3- (trifluoromethyl ) Phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (Compound 16)
  • Example 17 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (2-hydroxy-2-methylpropyl) -1-((3- (trifluoromethyl ) Phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (Compound 17)
  • Example 20 4- (7- (3- (difluoromethoxy) -5-fluorophenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) -1,2-dihydroquinazoline-3 (4H) -yl) -N, N-dimethylbutyramide (Compound 20)
  • Example 25 2- (7- (3- (difluoromethoxy) -5-fluorophenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) -1,2-dihydroquinazoline-3 (4H) -yl) -N, N-dimethylethylsulfonamide (Compound 25)
  • Example 26 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (oxetan-3-yl) -1-((3- (trifluoromethyl) Preparation of phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 26)
  • Example 29 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (tetrahydro-2H-pyran-4-yl) -1-((3- (trifluoromethyl Of phenyl) phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 29)
  • Example 30 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (oxetan-2-ylmethyl) -1-((3- (trifluoromethyl Of phenyl) phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 30)
  • Example 33 7- (3- (difluoromethoxy) -5-fluorophenyl) -3-((tetrahydro-2H-pyran-2-yl) methyl) -1-((3- Preparation of (trifluoromethyl) phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 33)
  • Example 36 7- (2-difluoromethoxyphenyl) -3- (2-methoxyethyl) -1-((3- (trifluoromethyl) phenyl) sulfonyl) -2, Preparation of 3-dihydroquinazoline-4 (1H) -one (Compound 36)
  • Example 38 7- (4-difluoromethoxyphenyl) -3- (2-methoxyethyl) -1-((3- (trifluoromethyl) phenyl) sulfonyl) -2, Preparation of 3-dihydroquinazoline-4 (1H) -one (Compound 38)
  • Example 50 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (2-methoxyethyl) -1-((3-methoxyphenyl) sulfonyl ) -2,3-Dihydroquinazolin-4 (1H) -one (Compound 50)
  • Example 51 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (2-methoxyethyl) -2,2-dimethyl-1-((3- Preparation of (trifluoromethyl) phenyl) sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (compound 51)
  • Step 1 Preparation of 7-bromo-3- (2-methoxyethyl) -2,2-dimethyl-2,3-dihydroquinazolin-4 (1H) -one
  • the palladium chloride methylene chloride complex (156 mg, 0.19 mmol) was replaced with nitrogen, and then heated to 80 ° C. for 4 hours to react.
  • the reaction solution was poured into water (100 mL) and extracted with ethyl acetate three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
  • the concentrate was purified by preparative high performance liquid chromatography to obtain the title compound of this step. (478 mg, yield: 63.2%).
  • Step 1 Preparation of 3- (2-amino-4-bromophenylformylamino) -2,2-dimethylpropanoate
  • Step 5 3- (7- (3- (difluoromethoxy) -5-fluorophenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) -1,2-dihydroquinazoline-3 (4H) -yl) -2,2-dimethylpropionic acid (Compound 52)
  • Example 54 3- (7- (3-fluorophenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) -1,2-dihydroquinazoline -3 (4H) -yl) -2,2-dimethylpropionic acid (Compound 54)
  • Example 63 3- (7- (3-chloro-5-methoxyphenyl) -4-oxo-1-((3- (trifluoromethyl) phenyl) sulfonyl) -1,2 -Dihydroquinazoline-3 (4H) -yl) -2,2-dimethylpropionic acid (Compound 63)
  • reaction solution was poured into water (150 mL), extracted three times with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title compound (362 mg, yield: 87.7%) in this step.
  • Example 64 7- (3- (difluoromethoxy) -5-fluorophenyl) -3- (2-morpholinylethyl) -1-((3- (trifluoromethyl) phenyl ) Sulfonyl) -2,3-dihydroquinazolin-4 (1H) -one (Compound 64)
  • Test example 1 ROR ⁇ -LBD TR-FRET experiment
  • Solution preparation Prepare a reaction buffer (25 mM HEPES, pH 7.0, 100 Mm NaCl, 0.01% Tween 20, 0.2% BSA, 5 mM DTT). Solution A1 containing 1nM LANCEEu-anti-6 ⁇ His antibody, solution A2 containing 1nM LANCEEu-anti-6 ⁇ His antibody and 15nM ROR ⁇ -LBD, and 200nM biotin-SRC1 and 15nM Allophycocyanin -Streptavidin's solution B, all kept on ice until use.
  • a reaction buffer 25 mM HEPES, pH 7.0, 100 Mm NaCl, 0.01% Tween 20, 0.2% BSA, 5 mM DTT.
  • compound activation rate (FI ratio compound- FI ratio solvent control ) / (FI ratio solvent control- FI ratio negative control ) * 100%
  • FI ratio indicates the fluorescence value (665nm) read by the microplate reader and the microplate reader The ratio of the fluorescence value (615 nm) was read; the EC 50 value was calculated by GraphPad Prism software.
  • the maximum activation rate refers to the activation rate of the corresponding concentration point when the curve obtained by the above formula for the activation rate of the compound is in the upper plateau phase; when the maximum activation rate is greater than 0, it indicates that the test compound has an agonistic effect on ROR ⁇ .
  • the agonistic activity of the test compound of the present invention on ROR ⁇ is shown in Table 1.
  • the compounds of the present invention has a significant effect on RORy agonist, having e.g. less than 10OnM, preferably less than 20 nM, more preferably less than 10 nM EC 50, the maximum activation rate of 40% or more.
  • Test example 2 ROR ⁇ -luciferase reporter gene experiment
  • Test compound (10 mM stock solution in DMSO)
  • 293T cells were cultured in a T25 cell culture flask in DMEM high-sugar medium (containing 10% FBS), and when grown to a confluency of about 80%, plasmid-containing liposomes were prepared according to the instructions of Lipofectamine 3000.
  • the liposome was mixed with a certain volume of DMEM high-sugar medium (containing 10% FBS), the original medium in the T25 culture flask was removed, and the mixed solution of the liposome and DMEM high-sugar medium was added to transfect 293T cells. 24 h after transfection, cells were digested and counted.
  • DMEM medium containing 10% FBS, 2 ⁇ M ursolic acid
  • DMEM high glucose medium containing 10% FBS, 2 ⁇ M ursolic acid
  • DMSO solvent control
  • the diluted compound and the solvent control were added to experimental wells and solvent control wells of a 96-well cell culture plate, respectively.
  • the cell culture plate was shaken for 2 minutes to thoroughly mix the compound with the culture medium, and the culture was continued in a 5% CO 2 incubator at 37 ° C. for 24 hours.
  • activation rate luminescence value of experimental wells / mean luminescence value of solvent control wells * 100%. The average luminescence value of the solvent control well was defined as 100%. Data analysis and graphing were performed using Graphpad Prism 5 software. The logarithm of activation rate and compound concentration was used to calculate the EC 50 value through a four-parameter fitting curve; The activation rate of the corresponding concentration point when the combined curve is in the upper plateau phase; when the maximum activation rate is greater than 100%, it indicates that the test compound has an agonistic effect on ROR ⁇ .
  • the compounds of the present invention have a significant agonistic effect on ROR ⁇ in cells, for example, an EC 50 of less than 1 ⁇ M and a maximum activation rate of more than 300%.

Abstract

本发明涉及一类苯并二氮杂环类化合物、其制备方法及用途以及含有所述化合物的药物组合物。特别是，本发明涉及式I化合物、其制备方法，式I化合物作为RORγ调节剂用于预防和/或治疗疾病的用途，以及含有式I化合物的药物组合物。

Description

苯并二氮杂环类化合物、其制备方法及用途 发明领域
本发明属于医药领域，具体涉及一类苯并二氮杂环类化合物、其制备方法及用途以及含有所述化合物的药物组合物。特别是，本发明涉及式I化合物、其制备方法，式I化合物作为RORγ调节剂用于预防和/或治疗疾病的用途，以及含有式I化合物的药物组合物。
发明背景
维A酸受体相关孤儿核受体(ROR)在多种生理过程中起调控作用，包括RORα，RORβ和RORγ三种亚型。近年的研究发现，相较于维A酸，RORs与氧化类固醇衍生物的亲和力更高，并为其所调控。RORs广泛分布于机体的各个组织中，能够直接进入细胞核调节靶基因的转录，进而参与不同生理过程，表现出不同的组织特异性。其中，RORα在各种组织中均有表达，但在大脑中高表达，在小脑发展和骨形成中起重要作用。RORβ作用范围较小，主要在大脑中表达，在视网膜、大脑皮层发展中起作用。RORγ可以在许多组织中表达，包括胸腺、肝脏和骨骼肌，在次级淋巴组织发展中起关键作用。
RORγ有RORγ1和RORγ2(RORγt)两种亚型。RORγ1在多种组织中表达，而RORγ2是特异性表达在免疫细胞上的亚型。RORγ2是Th17和Tc17效应T细胞分化与维持的关键转录因子，调节Th17细胞分泌效应因子IL-17，并在NK细胞、γδT细胞以及iNK T细胞的分化中起重要作用，这些细胞可介导免疫系统对抗癌细胞以及细菌、真菌等病原微生物。在肿瘤微环境中，Thl7细胞和IL-17可招募自然杀伤细胞和细胞毒性CD8+T细胞对肿瘤细胞进行攻击和杀伤。一些研究显示，卵巢癌病人肿瘤部位浸润Thl7细胞水平和IL-17表达水平与良好的预后呈正相关关系。
针对癌症的治疗，尽管已进行了大量的研究，付出了巨大的努力，其仍然是人类健康的一大威胁。无论在发达国家还是在发展中国家，癌症都是死亡率最高的疾病，并且发病率和死亡率仍不断增高。目前，针对肿瘤的治疗药物，并非对所有的肿瘤病人均有效。因此，开发具有调节RORγ活性的化合物可能对肿瘤的治疗将有助益，为肿瘤病人的治疗提供更多选择。目前，RORγ调节剂的开发在医药工业界已逐渐得到重视，已公开的专利申请包括WO2017157332A1、WO2011115892A1等。
然而，当前仍迫切需要研究和开发高活性、副作用少、抗耐药性、具有改善的药代动力学等性质的新的调节RORγ活性的化合物。
发明内容
本发明的一个方面提供式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
Figure PCTCN2019094579-appb-000001
环A 1选自苯基和5-10元杂芳基；
环A 2选自苯基、5-6元杂芳基和3-6元杂环基；
L为共价键或选自-C(R a)(R b)-和-C(R a)(R b)-C(R a)(R b)-；
R 1选自C 1-6烷基和4-10元杂环基；且可任选地被0、1、2或3个独立的选自下组的取代基所取代，该组取代基选自：卤素、-CN、-OH、-CO 2R 5a、-OR 6、-S(O) 2-R 6、-C(O)-N(R 5a)(R 5b)、-N(R 5a)C(O)R 6、-S(O) 2-N(R 5a)(R 5b)、-N(R 5a)S(O) 2R 6、4-10元杂环基、6-10元芳基和5-10元杂芳基；
每个R 2各自独立地选自卤素、氰基、羟基、C 1-6烷基、C 3-6环烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6卤代烷氧基和-O-C 3-6环烷基；
每个R 3各自独立地选自卤素、氰基、羟基、C 1-6烷基、C 1-6卤代烷基、C 3-6环烷基、C 1-6烷氧基、C 1-6卤代烷氧基和-S(O) 2-R 6；
每个R 4各自独立地选自卤素、氰基、C 1-6烷基和C 1-6烷氧基；
R 5a和R 5b各自独立地选自氢和C 1-6烷基；
或者R 5a、R 5b连同其相连的氮原子共同形成3-7元杂环基；
R 6选自C 1-6烷基和C 3-6环烷基；
每个R a和R b各自独立地选自氢和C 1-6烷基；
m为0、1、2或3；
n为0、1、2或3；
p为0、1或2。
在一些实施方案中，本发明提供了式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中所述式I化合物具有式II-A或II-B的结构，
Figure PCTCN2019094579-appb-000002
Figure PCTCN2019094579-appb-000003
其中：
每个R a和R b各自独立地选自氢和C 1-4烷基；
环A 1、环A 2、R 1、R 2、R 3、m和n定义如式I中所定义。
在一些实施方案中，本发明提供了式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：R 1选自C 1-4烷基和4-6元杂环基；且可任选地被0、1或2个独立的选自下组的取代基所取代，该组取代基包括：卤素、-CN、-OH、-CO 2R 5a、-OR 6、-S(O) 2-R 6、-C(O)-N(R 5a)(R 5b)、-N(R 5a)C(O)R 6、-S(O) 2-N(R 5a)(R 5b)、-N(R 5a)S(O) 2R 6、4-6元杂环基、6-10元芳基和5-10元杂芳基；更优选R 1选自C 1-4烷基、C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-CO 2R 5a、-C 1-4亚烷基-O-R 6、-C 1-4亚烷基-S(O) 2-R 6、-C 1-4亚烷基-C(O)-N(R 5a)(R 5b)、-C 1-4亚烷基-N(R 5a)C(O)R 6、-C 1-4亚烷基-S(O) 2-N(R 5a)(R 5b)和-C 1-4亚烷基-N(R 5a)S(O) 2R 6、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C 1-4亚烷基-氧杂环丁烷、-C 1-4亚烷基-四氢呋喃、-C 1-4亚烷基-四氢吡喃和-C 1-4亚烷基-吗啉；进一步优选R 1选自C 1-4烷基、C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-CO 2R 5a、-C 1-4亚烷基-O-R 6、-C 1-4亚烷基-S(O) 2-R 6、-C 1-4亚烷基-C(O)-N(R 5a)(R 5b)、-C 1-4亚烷基-N(R 5a)C(O)R 6、-C 1-4亚烷基-S(O) 2-N(R 5a)(R 5b)和-C 1-4亚烷基-N(R 5a)S(O) 2R 6、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C 1-4亚烷基-氧杂环丁烷、-C 1-4亚烷基-四氢呋喃、和-C 1-4亚烷基-四氢吡喃；
R 5a和R 5b各自独立地选自氢和C 1-4烷基；
或者R 5a、R 5b连同其相连的氮原子共同形成4-6元杂环基；
R 6选自C 1-4烷基和C 3-6环烷基；
优选地，R 1选自C 1-4烷基、C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-C(O)OH、-C 1-4亚烷基-C(O)O-C 1-4烷基、-C 1-4亚烷基-O-C 1-4烷基、-C 1-4亚烷基-O-C 3-6环烷基、-C 1-4亚烷基-S(O) 2-C 1-4烷基、-C 1-4亚烷基-C(O)-NH-C 1-4烷基、-C 1-4亚烷基-C(O)-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-NH-C(O)-C 1-4烷基、-C 1-4亚烷基-S(O) 2-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH-(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH 2、-C 1-4亚烷基-NH-S(O) 2-C 1-4烷基、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C 1-3亚烷基-氧杂环丁烷、-C 1-3亚烷基-四氢呋喃、-C 1-3亚烷基-四氢吡喃和-C 1-3亚烷基-吗啉；
优选地，R 1选自C 1-4烷基、C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-C(O)OH、-C 1-4亚烷基-C(O)O-C 1-4烷基、-C 1-4亚烷基-O-C 1-4烷基、-C 1-4亚烷基-O-C 3-6环烷基、-C 1-4亚烷基-S(O) 2-C 1-4烷基、-C 1-4亚烷基-C(O)-NH-C 1-4烷基、-C 1-4亚烷基-C(O)-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-NH-C(O)-C 1-4烷基、-C 1-4亚烷基-S(O) 2-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH-(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH 2、 -C 1-4亚烷基-NH-S(O) 2-C 1-4烷基、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C 1-3亚烷基-氧杂环丁烷、-C 1-3亚烷基-四氢呋喃、和-C 1-3亚烷基-四氢吡喃；
更优选地，R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2-CN、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2C(O)OH、-CH 2CH 2C(O)OH、-CH 2C(CH 3) 2C(O)OH、-CH 2C(O)O-CH 3、-CH 2CH 2C(O)O-CH 3、-CH 2C(CH 3) 2C(O)O-CH 3、-CH 2CH 2-O-CH 3、-CH 2CH(CH 3)-O-CH 3、-CH 2CH 2CH 2-O-CH 3、-CH 2CH 2-O-CH 2CH 3、-CH(CH 3)CH 2-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2、-CH 2CH 2-NH-S(O) 2-CH 3、
Figure PCTCN2019094579-appb-000004
Figure PCTCN2019094579-appb-000005
更优选地，R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2-CN、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2C(O)OH、-CH 2CH 2C(O)OH、-CH 2C(CH 3) 2C(O)OH、-CH 2C(O)O-CH 3、-CH 2CH 2C(O)O-CH 3、-CH 2C(CH 3) 2C(O)O-CH 3、-CH 2CH 2-O-CH 3、-CH 2CH(CH 3)-O-CH 3、-CH 2CH 2CH 2-O-CH 3、-CH 2CH 2-O-CH 2CH 3、-CH(CH 3)CH 2-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2、-CH 2CH 2-NH-S(O) 2-CH 3、
Figure PCTCN2019094579-appb-000006
Figure PCTCN2019094579-appb-000007
在一些实施方案中，本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：环A 1选自苯基和5-10元杂芳基；优选地，环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；更优选地，环A 1选自苯基和吡啶基。
在一些实施方案中，本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：R 2选自卤素、氰基、羟基、C 1-4烷基、C 3-6环烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-O-C 3-6环烷基；优选地，R 2选自卤素、氰基、C 3-6环烷基、C 1-4卤代烷基和C 1-4卤代烷氧基；更优选地，R 2选自氟、氯、氰基、甲基、甲氧基和二氟甲氧基。
在一些实施方案中，本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：环A 1 选自苯基和5-10元杂芳基；R 2选自卤素、氰基、羟基、C 1-4烷基、C 3-6环烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-O-C 3-6环烷基；
优选地，环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；R 2选自卤素、氰基、C 3-6环烷基、C 1-4卤代烷基和C 1-4卤代烷氧基；
更优选地，环A 1选自苯基和吡啶基；R 2选自卤素、氰基、C 1-4烷基、C 3-6环烷基、C 1-4烷氧基、C 1-4卤代烷基和C 1-4卤代烷氧基；
特别优选地，环A 1选自苯基和吡啶基；R 2选自氟、氯、氰基、甲基、甲氧基和二氟甲氧基。
在一些实施方案中，本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：环A 2选自苯基和5-6元杂芳基；优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基；更优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基。
在一些实施方案中，本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 3-6环烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-S(O) 2-C 1-4烷基；
优选地，在一些实施方案中，本发明提供式I、式II-A或式II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：环A 2选自苯基和5-6元杂芳基；R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 3-6环烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-S(O) 2-C 1-4烷基；
优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基；R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 1-4卤代烷氧基和-S(O) 2-C 1-4烷基。
特别优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基；R 3选自三氟甲基、甲基、氰基、氟和甲磺酰基。
在一些实施方案中，本发明提供式II-A或II-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；
环A 2选自苯基、吡啶基、异噁唑基和吡唑基；
R a和R b都是氢；
R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2-CN、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2C(O)OH、-CH 2CH 2C(O)OH、-CH 2C(CH 3) 2C(O)OH、-CH 2C(O)O-CH 3、-CH 2CH 2C(O)O-CH 3、-CH 2C(CH 3) 2C(O)O-CH 3、-CH 2CH 2-O-CH 3、-CH 2CH(CH 3)-O-CH 3、-CH 2CH 2CH 2-O-CH 3、-CH 2CH 2-O-CH 2CH 3、-CH(CH 3)CH 2-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2、 -CH 2CH 2-NH-S(O) 2-CH 3、
Figure PCTCN2019094579-appb-000008
Figure PCTCN2019094579-appb-000009
优选地，R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2-CN、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2C(O)OH、-CH 2CH 2C(O)OH、-CH 2C(CH 3) 2C(O)OH、-CH 2C(O)O-CH 3、-CH 2CH 2C(O)O-CH 3、-CH 2C(CH 3) 2C(O)O-CH 3、-CH 2CH 2-O-CH 3、-CH 2CH(CH 3)-O-CH 3、-CH 2CH 2CH 2-O-CH 3、-CH 2CH 2-O-CH 2CH 3、-CH(CH 3)CH 2-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2、-CH 2CH 2-NH-S(O) 2-CH 3、
Figure PCTCN2019094579-appb-000010
Figure PCTCN2019094579-appb-000011
每个R 2各自独立地选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基；
每个R 3各自独立地选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基和-S(O) 2-C 1-4烷基；
m为0、1、2或3；
n为0、1、2或3。
本发明的另一个方面提供式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
Figure PCTCN2019094579-appb-000012
环A 1选自苯基和5-10元杂芳基；
环A 2选自苯基、5-6元杂芳基和3-6元杂环基；
L为共价键或选自-C(R a)(R b)-和-C(R a)(R b)-C(R a)(R b)-；
R 1选自-C 1-6烷基；且可任选地被0、1、2或3个独立的选自下组的取代基所取代，该组取代基选自：卤素、-CN、-OH、-CO 2R 5a、-OR 6、-S(O) 2-R 6、-C(O)-N(R 5a)(R 5b)、-N(R 5a)C(O)R 6、-S(O) 2-N(R 5a)(R 5b)、-N(R 5a)S(O) 2R 6、6-10元芳基和5-10元杂芳基；
每个R 2各自独立地选自卤素、氰基、羟基、C 1-6烷基、C 3-6环烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6 卤代烷氧基和-O-C 3-6环烷基；
每个R 3各自独立地选自卤素、氰基、羟基、C 1-6烷基、C 1-6卤代烷基、C 3-6环烷基、C 1-6烷氧基、C 1-6卤代烷氧基和-S(O) 2-R 6；
每个R 4各自独立地选自卤素、氰基、C 1-6烷基和C 1-6烷氧基；
R 5a和R 5b各自独立地选自氢和C 1-6烷基；
或者R 5a、R 5b连同其相连的氮原子共同形成3-7元杂环基；
R 6选自C 1-6烷基和C 3-6环烷基；
每个R a和R b各自独立地选自氢和C 1-6烷基；
m为0、1、2或3；
n为0、1、2或3；
p为0、1或2。
在一些实施方案中，本发明提供了式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中所述式I化合物具有式II-A或II’-B的结构，
Figure PCTCN2019094579-appb-000013
其中：
每个R a和R b各自独立地选自氢和C 1-4烷基；
环A 1、环A 2、R 1、R 2、R 3、m和n定义如式I中所定义。
在一些实施方案中，本发明提供了式I、式II-A或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：R 1选自-C 1-4烷基；且可任选地被0、1或2个独立的选自下组的取代基所取代，该组取代基包括：卤素、-CN、-OH、-CO 2R 5a、-OR 6、-S(O) 2-R 6、-C(O)-N(R 5a)(R 5b)、-N(R 5a)C(O)R 6、-S(O) 2-N(R 5a)(R 5b)、-N(R 5a)S(O) 2R 6、6-10元芳基和5-10元杂芳基；更优选R 1选自-C 1-4烷基、-C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-CO 2R 5a、-C 1-4亚烷基-O-R 6、-C 1-4亚烷基-S(O) 2-R 6、-C 1-4亚烷基-C(O)-N(R 5a)(R 5b)、-C 1-4亚烷基-N(R 5a)C(O)R 6、-C 1-4亚烷基-S(O) 2-N(R 5a)(R 5b)和-C 1-4亚烷基-N(R 5a)S(O) 2R 6；
R 5a和R 5b各自独立地选自氢和C 1-4烷基；
或者R 5a、R 5b连同其相连的氮原子共同形成4-6元杂环基；
R 6选自C 1-4烷基和C 3-6环烷基；
优选地，R 1选自-C 1-4烷基、-C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-C(O)OH、-C 1-4亚烷基-C(O)O-C 1-4烷基、-C 1-4亚烷基-O-C 1-4烷基、-C 1-4亚烷基-O-C 3-6环烷基、-C 1-4亚烷基-S(O) 2-C 1-4烷基、-C 1-4亚烷基-C(O)-NH-C 1-4烷基、-C 1-4亚烷基-C(O)-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-NH-C(O)-C 1-4烷基、-C 1-4亚烷基-S(O) 2-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH-(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH 2和-C 1-4亚烷基-NH-S(O) 2-C 1-4烷基；
更优选地，R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2CH 2C(O)OH、-CH 2CH 2C(O)O-CH 3、-CH 2CH-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2和-CH 2CH 2-NH-S(O) 2-CH 3。
在一些实施方案中，本发明提供式I、式II-A或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：环A 1选自苯基和5-10元杂芳基；R 2选自卤素、氰基、羟基、C 1-4烷基、C 3-6环烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-O-C 3-6环烷基；
优选地，环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；R 2选自卤素、氰基、C 3-6环烷基、C 1-4卤代烷基、和C 1-4卤代烷氧基；
更优选地，环A 1选自苯基和吡啶基；R 2选自卤素、氰基、C 3-6环烷基、C 1-4卤代烷基、和C 1-4卤代烷氧基；
特别优选地，R 2选自氟、氰基、甲基、甲氧基和二氟甲氧基。
在一些实施方案中，本发明提供式I、式II-A或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：环A 2 选自苯基和5-6元杂芳基；R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 3-6环烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-S(O) 2-C 1-4烷基；
优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基；R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基和C 1-4卤代烷氧基。
特别优选地，R 3选自三氟甲基、甲基、氰基、氟和甲磺酰基。
在一些实施方案中，本发明提供式II-A或II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；
环A 2选自苯基、吡啶基、异噁唑基和吡唑基；
R a和R b都是氢；
R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2CH 2C(O)OH、-CH 2CH 2C(O)O-CH 3、-CH 2CH-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2和-CH 2CH 2-NH-S(O) 2-CH 3；
每个R 2各自独立地选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基；
每个R 3各自独立地选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基和-S(O) 2-C 1-4烷基；
m为0、1、2或3；
n为0、1、2或3。
在一些实施方案中，本发明提供选自以下的化合物：
Figure PCTCN2019094579-appb-000014
Figure PCTCN2019094579-appb-000015
Figure PCTCN2019094579-appb-000016
或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药。
本发明所述化合物中的原子可以被其同位素替代。例如 12C可被其同位素 13C或 14C替代； 1H可被 2H(D，氘)或 3H(T，氚)替代等。本发明包括式I、式II-A、式II-B或式II’-B所述化合物以及I、式II-A、式II-B或式II’-B化合物中的任意原子经其同位素替换后得到的同位素标记的化合物。
在本发明中，上面所定义的式I、式II-A、式II-B或式II’-B化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药也称为本发明化合物。
在另一方面，本发明还涉及制备式II-A的化合物的方法，所述方法包括以下步骤：
Figure PCTCN2019094579-appb-000017
其中，X表示离去基团，所述的离去基团包括但不限于卤素原子、甲磺酰基氧基、对甲基苯磺酰基氧基等。R 1、R 2、R 3、R a、R b、环A 1、环A 2、m、n如上面对式II-A化合物所定义；
(1)使化合物IN-A-1与化合物IN-A-2反应以得到化合物IN-A-3；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自四氢呋喃、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、1,4-二氧六环及其任意组合，优选四氢呋喃。所述反应优选在适合的缩合剂存在下进行。所述缩合剂可选自二环己基碳二亚胺、1-(3-二甲基氨基丙基)-3-乙基碳二亚胺、HATU、苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸酯、1H-苯并三唑-1-基氧三吡咯烷基六氟磷酸盐，优选HATU。所述反应优选在适合的有机碱存在下进行。所述有机碱可选自三乙胺、吡啶、4-二甲基氨基吡啶、二异丙基乙胺，优选二异丙基乙胺。所述反应优选在适合的温度下进行，所述温度优选为20-50℃。所述反应优选进行合适的时间，例如2-8小时。
(2)使化合物IN-A-3与化合物IN-A-4进行关环反应以得到化合物IN-A-5；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自醇类质子溶剂、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、1,4-二氧六环、乙腈及其任意组合。所述反应优选在适合的碱存在下进行。所述碱可选自氢氧化钠、氢氧化锂、氢氧化钾、甲醇钠、叔丁醇钠，优选氢氧化钠。所述反应优选在适合的温度下进行，所述温度优选为25-80℃。所述反应优选进行合适的时间，例如2-8小时。
特别地，当化合物IN-A-5中的R a与R b均为甲基时，也可以使化合物IN-A-3与2-甲氧基丙烯进行关环反应以得到化合物IN-A-5。所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自-丙酮、乙腈、丙腈、四氢呋喃、1,4-二氧六环及其任意组合，优选乙腈。所述反应优选在适合的酸存在下进行。所述酸可选自对甲苯磺酸、苯磺酸、樟脑磺酸、盐酸、硫酸，优选对甲苯磺酸。所述反应优选在适合的温度下进行，所述温度优选为25-80℃。所述反应优选进行合适的时间，例如2-8小时。
(3)使化合物IN-A-5与化合物IN-A-6反应以得到化合物IN-A-7；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮、甲苯、乙醇、乙二醇二甲醚、水、1,4-二氧六环及其任意组合，优选甲苯、乙醇、水的混合溶剂。所述反应优选在适合的缩合剂存在下进行。所述催化剂可选自各种钯催化剂，优选四(三苯基膦)钯。所述反应优 选在适合的碱存在下进行。所述碱可选自磷酸钾、醋酸钾、碳酸氢钠、碳酸钠、碳酸钾等，优选碳酸钠。所述反应优选在适合的温度下进行，所述温度优选为60-120℃。所述反应优选进行合适的时间，例如2-8小时。
(4)使化合物IN-A-7与化合物IN-A-8反应以得到式(II-A)的化合物；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自三乙胺、N,N-二异丙基乙基胺、吡啶及其任意组合，优选吡啶。所述反应优选在适合的温度下进行，所述温度优选为40-80℃。所述反应优选进行合适的时间，例如2-8小时。
本发明还涉及制备式II-B的化合物的方法，所述方法包括以下步骤：
Figure PCTCN2019094579-appb-000018
其中，X表示离去基团，所述的离去基团包括但不限于卤素原子、甲磺酰基氧基、对甲基苯磺酰基氧基等。R 1、R 2、R 3、R a、R b、环A 1、环A 2、m、n如上面对式II-B化合物所定义；
(1)使化合物IN-B-1与化合物IN-B-2反应以得到化合物IN-B-3；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自甲酸、冰醋酸等酸性溶剂及其任意组合，优选冰醋酸。所述反应优选在适合的温度下进行，所述温度优选为80-150℃。所述反应优选进行合适的时间，例如2-8小时。
(2)使化合物IN-B-3还原反应以得到化合物IN-B-4；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自乙醚、四氢呋喃、乙二醇二甲醚等惰性溶剂及其任意组合，优选四氢呋喃。所述反应优选在适合的还原试剂存在下进行。所述还原试剂可选自四氢铝锂、硼烷、红铝等，优选四氢铝锂。所述反应优选在适合的温度下进行，所述温度优选为20-50℃。所述反应优选进行合适的时间，例如2-8小时。
(3)使化合物IN-B-4与化合物IN-A-8反应以得到化合物IN-B-5；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自三乙胺、N,N-二异丙基乙胺、吡啶及其任意组合，优选吡啶。所述反应优选在适合的温度下进行，所述温度优选为40-80℃。所述反应优选进行合适的时间，例如2-8小时。
(4)使化合物IN-B-5与化合物IN-A-6反应以得到化合物IN-B-6；
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮、甲苯、乙醇、乙二醇二甲醚、水、1,4-二氧六环及其任意组合，优选甲苯、乙醇、水的混合溶剂。所述反应优选在适合的缩合剂存在下进行。所述催化剂可选自各种钯催化剂，优选四(三苯基膦)钯。所述反应优选在适合的碱存在下进行。所述碱可选自磷酸钾、醋酸钾、碳酸氢钠、碳酸钠、碳酸钾等，优选碳酸钠。所述反应优选在适合的温度下进行，所述温度优选为60-120℃。所述反应优选进行合适的时间，例如2-8小时。
(5)使化合物IN-B-6与化合物IN-B-7反应以得到式(II-B)的化合物。
所述反应优选在适合的有机溶剂中进行。所述有机溶剂可选自N,N-二甲基甲酰胺、N-甲基吡咯烷酮、四氢呋喃等及其任意组合，优选N,N-二甲基甲酰胺。所述反应优选在适合的碱存在下进行。所述碱可选自氢化钠，叔丁醇钾、叔丁醇钠，甲醇钠等，优选叔丁醇钾。所述反应优选在适合的温度下进行，所述温度优选为10-40℃。所述反应优选进行合适的时间，例如2-8小时。
上述各反应步骤的具体条件为本领域公知，对此本发明不作具体限定。根据本发明的教导结合本领域公知常识，本领域技术人员可以对通式中的各取代基进行选择替换以制备得到不同的化合物，这些选择和替换均在本发明的保护范围之内。
本发明还涉及药物组合物，其包含本发明化合物，以及任选地，一种或多种药学上可接受的载体或赋形剂。
本发明还涉及药物制剂，其包含本发明化合物，或其药物组合物。
本发明还涉及本发明化合物、其药物组合物、或其药物制剂在制备作为维A酸受体相关孤儿核受体γ(RORγ)调节剂的药物中的用途。
本发明还涉及本发明化合物或其药物组合物、或其药物制剂在制备用于预防和/或治疗RORγ介导的疾病或病症的药物中的用途。在一实施方案中，所述药物还包含其他抗肿瘤剂。
本发明还涉及一种预防和/或治疗RORγ介导的疾病或病症的方法，其包括向有需要的受试者施用有效量的本发明化合物、其药物组合物、或其药物制剂。
本发明还涉及本发明化合物、其药物组合物、或其药物制剂，其用于预防和/或治疗RORγ介导的疾病或病症。
本发明还涉及本发明化合物、其药物组合物、或其药物制剂，其用于调节维A酸受体相关孤儿核受体γ(RORγ)。
在一些实施方案中，所述RORγ介导的疾病或病症选自肿瘤或癌症，例如非霍奇金淋巴瘤、弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、滑膜肉瘤、乳腺癌、宫颈癌、结肠癌、肺癌、口腔癌、脑癌、胃癌、肝癌、直肠癌、胰腺癌、皮肤癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、输卵管肿瘤、腹膜肿瘤、黑色素瘤、实体瘤、神经胶质瘤、神经胶母细胞瘤、乳突状恶性瘤、头颈部肿瘤、白血病、淋巴瘤或骨髓瘤。
本发明中，将活性成分制备成药物组合物的目的是便于或有利于生物体的给药，利于活性成分的吸收进而发挥生物活性。
所述赋形剂是指在药物制剂中除主药以外的附加物。其性质稳定，与主药无配伍禁忌，不产生副作用， 不影响疗效，在常温下不易变形、干裂、霉变、虫蛀、对人体无害、无生理作用，不与主药产生化学或物理作用，不影响主药的含量测定等。
本发明的化合物可以通过以下途径给药：胃肠外、局部、静脉内、口服、皮下、动脉内、真皮内、经皮、直肠、颅内、腹膜内、鼻内、肌内途径或作为吸入剂。本发明的化合物可以任选地与在治疗本发明所述的各种疾病中至少有一定效果的其它活性成分联合给药。
本发明的化合物可根据给药途径配成各种适宜的剂型。
本发明所述的药物组合物或适宜的剂型可以含有0.01mg至1000mg的本发明化合物。
当口服用药时，本发明的化合物可制成任意口服可接受的制剂形式，包括但不限于片剂、胶囊、水溶液或水悬浮液。
当皮肤局部施用时，本发明的化合物可制成适当的软膏、洗剂或霜剂制剂形式，其中将活性成分悬浮或溶解于一种或多种载体中。
本发明的化合物还可以无菌注射制剂形式用药，包括无菌注射水或油悬浮液或无菌注射溶液。
在本发明的实施方案中，进行合适的体外或体内测定来确定本发明药物组合物的效果以及给药是否适用于治疗个体所患疾病或医学疾病状态。这些测定的实例在下文非限制性实施例结合具体疾病或医学治疗进行了描述。通常，足以实现预防或治疗效果的本发明组合物的有效量为约0.001mg/千克体重/天至约10,000mg/千克体重/天。剂量和频率根据制剂在受试者中的半衰期而不同。也可以根据是预防性处理还是治疗性处理而不同。在预防性应用中，以相对低频率的间隔长期给予相对低的剂量。在治疗性应用中，有时需要以相对短的间隔给予相对高的剂量，直至疾病的进展被延缓或停止，并优选地直至个体表现出疾病症状的部分或完全改善，在此之后，可以给予患者预防方案。
定义
以下对本发明的术语进行解释，对于特定的术语，如果本发明中的含义与本领域技术人员通常理解的含义不一致，以本发明中的含义为准；如果在本发明中没有定义，则其具有本领域技术人员通常理解的含义。除非有相反陈述，本发明中使用的术语具有下述含义：
本发明所用术语“包括”、“包含”、“具有”、“含有”或“涉及”及其在本文中的其它变体形式为开放式的，且不排除其它未列举的元素或方法步骤。
本发明所用术语“氢”及所述的各基团中的氢，是指氕(H)，氘(D)或氚(T)。
本发明所用术语“卤素”是指氟、氯、溴或碘。
本发明所用术语“共价键”是指两个原子共同使用它们的外层电子，在理想情况下达到电子饱和的状态，由此组成比较稳定的化学结构。基于价键理论，式(I)的L中的共价键是指L相邻的两个N原子间共用一对电子而构成的单键。
本发明所用术语“C 1-6烷基”是指具有1-6个碳原子的直链或支链烷基，例如C 1-4烷基、C 1-2烷基、C 1烷基、C 2烷基、C 3烷基、C 4烷基、C 5烷基或C 6烷基。具体的实例包括但不限于甲基、乙基、丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、正己基等。
本发明所用术语“C 1-6卤代烷基”是指被一个或多个卤素原子取代的具有1-6个碳原子的直链或支链烷基，例如C 1-4卤代烷基、C 1-2卤代烷基、C 1卤代烷基、C 2卤代烷基、C 3卤代烷基、C 4卤代烷基、 C 5卤代烷基或C 6卤代烷基。具体的实例包括但不限于三氟甲基、二氟甲基、三氟乙基、单氟甲基等。
本发明所用术语“C 1-6烷氧基”是指C 1-6烷基-O-基团，其中C 1-6烷基具有上面所定义的含义。
本发明所用术语“C 1-6卤代烷氧基”是指C 1-6卤代烷基-O-基团，其中C 1-6卤代烷基具有上面所定义的含义。
本发明所用术语“C 1-6亚烷基”是指本文中定义的C 1-6烷基去除一个氢后形成的直链或支链二价烷基，例如C 1-4亚烷基、C 1-2亚烷基、C 1亚烷基、C 2亚烷基、C 3亚烷基、C 4亚烷基、C 5亚烷基或C 6亚烷基。具体的实例包括但不限于-CH 2-、-CH(CH 3)-、-CH 2CH 2-、-CH 2CH(CH 3)-、-CH(CH 3)CH 2-、-CH 2CH 2CH 2-、-CH 2CH 2CH 2CH 2-、-CH 2C(CH 3) 2-、-CH 2CH 2CH 2CH 2CH 2-、-CH 2CH 2CH 2CH(CH 3)-、-CH 2CH 2C(CH 3) 2-、-CH 2CH 2CH 2CH 2CH 2CH 2-等。
本发明所用术语“C 3-6环烷基”是指含有3-6个碳原子的饱和或部分饱和的单环烷基，例如3元、4元、5元或6元环烷基。具体的实例包括但不限于环丙基、环丁基、环戊基、环己基等。
本发明所用术语“6-10元芳基”是指在环部分具有6-10个碳原子的单环或二环芳香烃基团，例如苯基。
本发明所用术语“5-10元杂芳基”是指含有5-10个环成员的单环或多环芳香族基团，且所述环成员中至少1个至多4个(例如1、2、3或4个)为选自N、O和S的杂原子。本发明所用术语“5-6元杂芳基”是指含有5-6个环成员的单环芳香族基团，且所述环成员中至少1个至多4个(例如1、2、3或4个)为选自N、O和S的杂原子，例如5元杂芳基、6元杂芳基等。杂芳基的具体的实例包括但不限于呋喃基、噻吩基、吡咯基、噻唑基、异噻唑基、噻二唑基、噁唑基、异噁唑基、咪唑基、吡唑基、1,2,3-三唑基、1,2,4-三唑基、1,2,3-噁二唑基、1,2,4-噁二唑基、1,2,5-噁二唑基、1,3,4-噁二唑基、吡啶基、2-吡啶酮基、4-吡啶酮基、嘧啶基、2H-1,2-噁嗪基、4H-1,2-噁嗪基、6H-1,2-噁嗪基、4H-1,3-噁嗪基、6H-1,3-噁嗪基、4H-1,4-噁嗪基、哒嗪基、吡嗪基、1,2,3-三嗪基、1,3,5-三嗪基、1,2,4,5-四嗪基、咪唑并[1,2-a]吡啶基等。特别地，杂芳基的具体的实例包括但不限于吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基。
本发明所用术语“4-10元杂环基”是指含有4-10个环成员的完全饱和的或部分饱和的环状基团，例如3-7个环成员、或4-6个环成员，所述环成员中至少1个例如1、2或3个选自N、C(＝O)、O、S、S(＝O)、和S(＝O) 2，其余的环成员为C原子。例如，杂环基为包含1或2个选自N、O和S的4-6元杂环基，如
Figure PCTCN2019094579-appb-000019
Figure PCTCN2019094579-appb-000020
如果取代基被描述为“任选地被…取代”，则取代基可(1)未被取代或(2)被取代。如果取代基的碳被描述为任选地被取代基列表中的一个或多个取代，则碳上的一个或多个氢(至存在的任何氢的程度)可单独和/或一起被独立地选择的任选的取代基替代。如果取代基的氮被描述为任选地被取代基列表中的一个或多个取代，则氮上的一个或多个氢(至存在的任何氢的程度)可各自被独立地选择的任选的取代基替代。所述取代基包括但不限于卤素、氰基、羟基、C 1-6烷基、C 3-6环烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6卤代烷氧基、 -O-C 3-6环烷基、芳基例如苯基、5-6元杂芳基和5-6杂环基等。
本发明所用术语“一个或多个”是指在合理条件下的1个或超过1个，例如2个、3个、4个、5个或10个。
除非指明，否则如本文中所使用，取代基的连接点可来自取代基的任意适宜位置。
本发明所用术语“立体异构体”表示由于至少一个不对称中心形成的异构体。在具有一个或多个(例如1个、2个、3个或4个)不对称中心的化合物中，其可产生外消旋混合物、单一对映异构体、非对映异构体混合物和单独的非对映异构体。特定个别分子也可以几何异构体(顺式/反式)存在。本发明的化合物可以两种或更多种处于快速平衡的结构不同的形式的混合物(通常称作互变异构体)存在。互变异构体的代表性实例包括酮-烯醇互变异构体、苯酚-酮互变异构体、亚硝基-肟互变异构体、亚胺-烯胺互变异构体等。要理解，本申请的范围涵盖所有这样的以任意比例(例如60％、65％、70％、75％、80％、85％、90％、95％、96％、97％、98％、99％)的异构体或其混合物。
除非另外指明，否则本发明的化合物意欲可以立体异构体(其包括顺式及反式异构体、光学异构体(例如R及S对映异构体)、非对映异构体、几何异构体、旋转异构体、构象异构体、阻转异构体及其混合物)的形式存在。本发明的化合物可表现一种以上类型的异构现象，且由其混合物(例如外消旋混合物及非对映异构体对)组成。
本发明涵盖本发明的化合物的所有可能的结晶形式或多晶型物，其可为单一多晶型物或多于一种多晶型物的任意比例的混合物。
本发明的化合物可以溶剂合物(如水合物)的形式存在，其中本发明的化合物包含作为所述化合物晶格的结构要素的极性溶剂，特别是例如水、甲醇或乙醇。极性溶剂特别是水的量可以化学计量比或非化学计量比存在。
本发明的化合物或其药学上可接受的盐还可以形成溶剂合物，例如醇合物等。
本发明的化合物还可以是前药或以或可在体内代谢变化后释放出所述活性成分的形式。如本所用，“前药”是指被化学修饰的活性或非活性的化合物，给药至受试者后，其经过体内的生理作用(例如水解、新成代谢等)变为本发明化合物。选择和制备适当的前药衍生物是本领域技术人员公知技术。
本发明的化合物还可以是化学保护的形式，所述保护基可保护在化合物的活性基团(如氨基)上，所述保护基可在体内代谢释放出活性成分。选择和制备适当的化学保护的形式是本领域技术人员公知技术。
本发明所用术语“药学上可接受的”是指物质或组合物必须与构成制剂的其他组分和/或用其治疗的受试者在化学和/或毒理学上相容。
本发明所用术语“药学上可接受的盐”包括与药学上可以接受的无机酸或者有机酸、或者无机碱或有机碱形成的常规盐。示例性的酸加成盐包括，例如，无机酸盐如盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硝酸盐、磷酸盐(如，例如，磷酸盐、磷酸氢盐或磷酸二氢盐)、碳酸盐、碳酸氢盐或高氯酸盐；有机酸盐如乙酸盐、丙酸盐、丁酸盐、戊酸盐、己酸盐、庚酸盐、辛酸盐、环戊烷丙酸盐、十一酸盐、乳酸盐、苹果酸盐、草酸盐、富马酸盐、酒石酸盐、马来酸盐、柠檬酸盐、烟酸盐、苯甲酸盐、水杨酸盐或抗坏血酸盐；磺酸盐如甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、对甲苯磺酸盐、2-萘磺酸盐、3-苯基磺酸盐或樟脑磺酸盐；酸性氨基酸盐如天冬氨酸盐或谷氨酸盐。本发明所用术语“药物组合物”包括包含治疗有效 量的本发明式I的化合物的产品，以及直接地或间接地由本发明式I化合物的组合产生的任何产品。
本发明所用术语“有效量”是指足以实现所需治疗效果的量，例如，实现减轻与待治疗疾病相关的症状的量。
本发明所用的术语“治疗”目的是减轻或消除所针对的疾病状态或病症。如果受试者按照本文所述方法接受了治疗量的化合物、其光学异构体或其药学上可接受的盐或其药物组合物，该受试者一种或多种指征和症状表现出可观察到的和/或可检测出的降低或改善，则受试者被成功地“治疗”了。还应当理解，所述的疾病状态或病症的治疗的不仅包括完全地治疗，还包括未达到完全地治疗，但实现了一些生物学或医学相关的结果。
如本文所用，术语“受试者”指动物，例如哺乳动物。受试者还指例如灵长类(例如人类)、牛、绵羊、山羊、马、狗、猫、兔、大鼠、小鼠、鱼、鸟等。
具体实施方式
为了使本发明的目的和技术方案更加清楚，以下结合具体实施例进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。并且，下列实施例中未提及的具体实验方法，均按照常规实验方法进行。
在本申请中，当化学名称和结构式不一致时，应当以结构式所示为准，除非根据上下文可以推断化学名称而非结构式是正确的。
本文中的缩写具有以下含义：
缩写 含义
TLC 薄层色谱法
LC-MS 液相色谱-质谱联用
DIPEA N,N-二异丙基乙胺
HATU 2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯
DMF N,N-二甲基甲酰胺
CD 3OD 氘代甲醇
CDCl 3 氘代氯仿
DMSO-d 6 六氘代二甲基亚砜
TMS 四甲基硅烷
NMR 核磁共振
MS 质谱
s 单峰(singlet)
d 二重峰(doublet)
t 三重峰(triplet)
q 四重峰(quartet)
dd 双二重峰(double doublet)
m 多重峰(multiplet)
br 宽峰(broad)
J 偶合常数
Hz 赫兹
以下实施例中记载的化合物的结构通过 1H-NMR或MS来确证。 1H-NMR的测定仪器使用Bruker 400MHz核磁共振仪，测定溶剂为CD 3OD、CDCl 3或DMSO-d 6，内标物质为TMS，全部δ值用ppm值表示。质谱(MS)的测定仪器使用Agilent(ESI)质谱仪，型号为Agilent 6120B。
薄层色谱硅胶板(TLC)使用Merck产的铝板(20×20cm)，薄层层析分离纯化采用的是GF 254(0.4～0.5mm)。
反应的监测采用薄层色谱法(TLC)或LC-MS，使用的展开剂体系有：二氯甲烷和甲醇体系，正己烷和乙酸乙酯体系，石油醚和乙酸乙酯体系，溶剂的体积比根据化合物的极性不同而进行调节或者加入三乙胺等进行调节。
柱层析一般使用200～300目硅胶为载体。洗脱剂的体系包括：二氯甲烷和甲醇体系，石油醚和乙酸乙酯体系，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺进行调节。
制备高效液相色谱仪，仪器型号：Agilent 1260，色谱柱：Waters XBridge Prep C 18OBD(19mm×150mm×5.0μm)；色谱柱温：25℃；流速：20.0mL/min；检测波长：214nm；洗脱梯度：(0min：10％A，90％B；16.0min：90％A，10％B)；流动相A：100％乙腈；流动相B：0.05％碳酸氢铵水溶液。
除非特别指出，实施例的反应温度为室温(20℃～30℃)。
本发明所使用的试剂购自Acros Organics、Aldrich Chemical Company、上海特伯化学科技有限公司等。
实施例
实施例1：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(化合物1)的制备
Figure PCTCN2019094579-appb-000021
第一步：3-(2-氨基-4-溴苯基甲酰基氨基)丙酸甲酯的制备
将2-氨基-4-溴苯甲酸(1.0g,4.63mmol)、3-氨基丙酸甲酯盐酸盐(0.72g,6.94mmol)和HATU(2.64g,6.94mmol)加入四氢呋喃(10mL)中，室温搅拌下缓慢加入DIPEA(1.79g,13.9mmol)后维持室温反应4小 时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(1.1g，收率：78.9％)。
MS m/z(ESI):301.0[M+H] +。
第二步：3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸的制备
将3-(2-氨基-4-溴苯基甲酰基氨基)丙酸甲酯(1.0g,3.32mmol)、氢氧化钠(146.3mg,3.66mmol)混溶于乙醇(50mL)中，加入37％甲醛水溶液(3.32mmol,2.91mL)后，加热至60℃反应3小时。将反应液减压浓缩后加入水(100mL)，2N稀盐酸调节pH＝7左右，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(0.9g，收率：90.6％)。
MS m/z(ESI):299.0[M+H] +。
第三步：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸的制备
将3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸(200mg,668.6μmol)和2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(289mg,1.0mmol)溶于甲苯(6mL)、水(2mL)和乙醇(2mL)的混合溶剂中，加入四(三苯基膦)钯(38.6mg,33.4μmol)和碳酸钠(141.8mg,1.34mmol)后，氮气置换后加热至90℃反应4小时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(0.21g，收率：83.6％)。
MS m/z(ESI):381.1[M+H] +。
第四步：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸(50mg,0.13mmol)溶于甲醇(2mL)中，冰浴下加入二氯亚砜(16mg,0.13mmol)，加热至70℃反应2小时。将反应液浓缩后倾入水(50mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(50mg，收率：96.4％)。
MS m/z(ESI):395.1[M+H] +。
第五步：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(化合物1)的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(60.0mg,152.2μmol)完全溶于吡啶(5mL)中，加热至60℃，加入分子筛(120.0mg)，搅拌约30分钟后，加入3-三氟甲基苯磺酰氯(38.0mg,152.2μmol)，维持60℃反应4小时。冷却至室温后，减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(23.0mg，收率：25.1％)。
MS m/z(ESI):603.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.09-8.07(m,1H),7.99-7.98(m,1H),7.90-7.87(m,1H),7.84-7.82(m,1H),7.78-7.70(m,3H),7.48(t,J＝72.8Hz,1H),7.60-7.57(m,1H),7.48-7.46(m,1H),7.29-7.27(m,1H),5.33(s,2H),3.59(s,3H),3.40-3.38(m,2H),2.49-2.46(m,2H)。
实施例2：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸(化合物2)的制备
Figure PCTCN2019094579-appb-000022
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯(170.0mg,282.2μmol)溶于甲醇(2mL)、四氢呋喃(2mL)和水(2mL)的混合溶剂中，加入氢氧化钠(12.0mg,282.2μmol)，继续于25℃搅拌反应4小时。将反应液倾倒入水(100mL)中，2N稀盐酸调节pH＝2，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(50.0mg，收率：30.1％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.96-7.93(m,2H),7.81-7.76(m,2H),7.61-7.50(m,3H),7.28-7.24(m,2H),6.98-6.96(m,1H),6.61(t,J＝72.8Hz,1H),5.29-5.26(m,2H),5.43-5.40(m,2H),2.68-2.65(m,2H)。
实施例3：3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000023
-4(5H)-基)丙酸甲酯(化合物3)的制备
Figure PCTCN2019094579-appb-000024
第一步：8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000025
-2,5-二酮的制备
4-溴靛红酸酐(1.0g,4.1mmol)和甘氨酸(465.2mg,6.2mmol)完全溶解于冰乙酸(10mL)，加热至120℃反应4小时。冷却至室温后，将反应液倾入水(100mL)中，抽滤并用水(100mL)洗涤固体，得到本步的标题化合物(1.0g，收率：91.09％)。
MS m/z(ESI):255.0[M+H] +。
第二步：8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000026
-5(2H)-酮的制备
将四氢铝锂(149.0mg,3.9mmol)分散至无水四氢呋喃(10mL)中，加入8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000027
-2,5-二酮(500.0mg,2.0mmol)后，于25℃反应4小时。向反应液中缓慢加入十水硫酸钠淬灭反应，抽滤并用乙酸乙酯(100mL)洗涤固体，浓缩滤液得到本步的标题化合物(150.0mg，收率：31.7％)。
MS m/z(ESI):241.0[M+H] +。
第三步：8-溴-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000028
-5(2H)-酮的制备
将8-溴-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000029
-5(2H)-酮(150.0mg,622.2μmol)完全溶解于吡啶(5mL)中，加热至60℃，加入分子筛(250.0mg)搅拌约30分钟后，加入3-三氟甲基苯磺酰氯(228.3mg,933.3μmol)和4-二甲氨基吡啶(5.0mg,40.1μmol)，维持60℃反应4小时。冷却至室温后，减压浓缩，浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(72.0mg，收率：25.7％)。
MS m/z(ESI):449.0[M+H] +。
第四步：8-(3-(二氟甲氧基)-5-氟苯基)-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000030
-5(2H)-酮的制备
将8-溴-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000031
-5(2H)-酮(70.0mg,155.8μmol)、2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(90.0mg,0.3mmol)、[1,1'-双(二苯基膦基)二茂铁]二氯化钯(6.0mg,7.8μmol)和碳酸钾(64.5mg,0.5mmol)溶于1,4-二氧六环(4mL)和水(2mL)混合溶剂中，氮气置换后加热至80℃反应4小时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(71.0mg，收率：86.0％)。
MS m/z(ESI):531.1[M+H] +。
第五步：3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000032
-4(5H)-基)丙酸甲酯(化合物3)的制备
将8-(3-(二氟甲氧基)-5-氟苯基)-1-((3-(三氟甲基)苯基)磺酰基)-3,4-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000033
-5(2H)-酮(70.0mg,132.0μmol)溶于DMF(5mL)中，加入叔丁醇钾(14.8mg,132.0μmol)，于25℃搅拌10分钟后，加入3-溴丙酸甲酯(22.1mg,132.0μmol)，继续于25℃搅拌反应4小时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(42.0mg，收率：51.6％)。
MS m/z(ESI):617.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.09-8.07(m,1H),7.94-7.91(m,1H),7.80-7.76(m,4H),7.60-7.54(m,2H),7.47(t,J＝72.8Hz,1H),7.45-7.42(m,1H),7.26-7.23(m,1H),4.06-4.03(m,2H),3.58(s,3H),3.33-3.30(m,2H),3.12(t,J＝7.2Hz,2H),2.33(t,J＝7.2Hz,2H)。
实施例4：3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000034
-4(5H)-基)丙酸(化合物4)的制备
Figure PCTCN2019094579-appb-000035
将3-(8-(3-(二氟甲氧基)-5-氟苯基)-5-氧代-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢-1H-苯并[e][1,4]二氮杂
Figure PCTCN2019094579-appb-000036
-4(5H)-基)丙酸甲酯(100.0mg,162.2μmol)溶于甲醇(2mL)、四氢呋喃(2mL)和水(2mL)的混合溶剂中，加入氢氧化钠(13.0mg,324.4μmol)，继续于25℃搅拌反应4小时。将反应液倾倒入水(100mL)中，2N稀盐 酸调节pH＝2，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(60.0mg，收率：58.3％)。
MS m/z(ESI):603.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:12.32(br,1H),8.09-8.07(m,1H),7.94-7.91(m,1H),7.84-7.76(m,4H),7.60-7.54(m,2H),7.47(t,J＝72.8Hz,1H),7.44-7.42(m,1H),7.26-7.23(m,1H),4.06-4.03(m,2H),3.33-3.31(m,2H),3.09(t,J＝7.2Hz,2H),2.24(t,J＝7.2Hz,2H)。
实施例5：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物5)的制备
Figure PCTCN2019094579-appb-000037
第一步：2-氨基-4-溴-N-(2-甲氧乙基)苯甲酰胺的制备
将2-氨基-4-溴苯甲酸(500mg,2.3mmol)、2-甲氧基乙胺(261mg,3.5mmol)和HATU(1.8g,4.6mmol)加入四氢呋喃(10mL)中，室温搅拌下缓慢加入DIPEA(0.9g,6.9mmol)后维持室温反应4小时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(600mg，收率：94.9％)。
MS m/z(ESI):273.0[M+H] +。
第二步：7-溴-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮的制备
将2-氨基-4-溴-N-(2-甲氧乙基)苯甲酰胺(500mg,1.8mmol)和氢氧化钠(81mg,2.0mmol)混溶于乙醇(8mL)中，加入37％甲醛水溶液(2.0mmol,0.15mL)后，加热至60℃反应3小时。将反应液减压浓缩后加入水(100mL)，2N盐酸调节pH＝7左右，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(500mg，收率：95.8％)。
MS m/z(ESI):285.0[M+H] +。
第三步：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮的制备
将7-溴-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮(500mg,1.8mmol)和2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(1.01g,3.51mmol)溶于1,4-二氧六环(16mL)和水(4mL)的混合溶剂中，加入[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(215mg,0.26mmol)和碳酸钾(730mg,5.3mmol)，氮气置换后，加热至80℃反应4小时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(600mg，收率：93.4％)。
MS m/z(ESI):367.1[M+H] +。
第四步：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉 -4(1H)-酮(化合物5)的制备
将7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,3-二氢喹唑啉-4(1H)-酮(300mg,0.82mmol)完全溶于吡啶(5mL)中，加入3-三氟甲基苯磺酰氯(300mg,1.23mmol)，加热至60℃反应4小时。冷却至室温后，减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(98mg，收率：20.8％)。
MS m/z(ESI):575.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.98-7.96(m,1H),7.88-7.81(m,3H),7.81-7.72(m,2H),7.59-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.31(s,2H),3.39-3.36(m,4H),3.25(s,3H)。
实施例6：(S)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物6)的制备
Figure PCTCN2019094579-appb-000038
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(S)-2-甲氧基丙-1-胺盐酸盐，得到标题化合物(74mg，收率：29.8％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.98-7.96(m,1H),7.89-7.86(m,1H),7.84-7.82(m,1H),7.79-7.76(m,1H),7.74-7.70(m,2H),7.58-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.32(s,2H),3.43-3.40(m,2H),3.26-3.23(m,4H),0.98-0.96(m,3H)。
实施例7：(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物7)的制备
Figure PCTCN2019094579-appb-000039
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(R)-2-甲氧基丙-1-胺盐酸盐，得到标题化合物(77mg，收率：26.3％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.98-7.95(m,1H),7.89-7.86(m,1H),7.84-7.82(m,1H),7.80-7.76(m,1H),7.74-7.70(m,2H),7.58-7.55(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.29-7.27(m,1H),5.32(s,2H),3.43-3.40(m,2H),3.26-3.23(m,4H),0.98-0.96(m,3H)。
实施例8：7-(3-(二氟甲氧基)-5-氟苯基)-3-(3-甲氧基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物8)的制备
Figure PCTCN2019094579-appb-000040
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为3-甲氧基丙胺，得到标题化合物(56mg，收率：26.9％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.98-7.96(m,1H),7.89-7.83(m,2H),7.56-7.69(m,3H),7.58-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.28-7.26(m,1H),5.30(s,2H),3.28-3.25(m,2H),3.24-3.20(m,5H),1.65-1.59(m,2H)。
实施例9：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-乙氧基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物9)的制备
Figure PCTCN2019094579-appb-000041
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为2-乙氧基乙胺，得到标题化合物(74mg，收率：26.8％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.98-7.96(m,1H),7.88-7.81(m,3H),7.76-7.70(m,2H),7.58-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.44(m,1H),7.28-7.26(m,1H),5.32(s,2H),3.46-3.33(m,6H),1.12-1.09(m,3H)。
实施例10：(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(1-甲氧基丙-2-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二 氢喹唑啉-4(1H)-酮(化合物10)的制备
Figure PCTCN2019094579-appb-000042
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(R)-1-甲氧基-2-丙胺盐酸盐，得到标题化合物(69mg，收率：25.6％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.93-7.89(m,2H),7.87-7.81(m,3H),7.77-7.73(m,1H),7.54-7.51(m,1H),7.47(t,J＝72.8Hz,1H),7.42-7.39(m,1H),7.28-7.26(m,1H),5.31-5.18(m,2H),4.48-4.43(m,1H),3.48-3.45(m,1H),3.36-3.32(m,1H),3.25(s,3H),1.05(d,J＝8.0Hz,3H)。
实施例11：7-(3-(二氟甲氧基)-5-氟苯基)-3-(1-甲氧基丙-2-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物11)的制备
Figure PCTCN2019094579-appb-000043
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为1-甲氧基-2-丙胺盐酸盐，得到标题化合物(69mg，收率：25.6％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.93-7.90(m,2H),7.87-7.81(m,3H),7.77-7.73(m,1H),7.54-7.50(m,1H),7.47(t,J＝72.8Hz,1H),7.42-7.39(m,1H),7.28-7.26(m,1H),5.31-5.19(m,2H),4.48-4.43(m,1H),3.48-3.45(m,1H),3.36-3.32(m,1H),3.25(s,3H),1.05(d,J＝8.0Hz,3H)。
实施例12：7-(3-(二氟甲氧基)-5-氟苯基)-3-甲基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物12)的制备
Figure PCTCN2019094579-appb-000044
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为甲胺，得到标题化合物(72mg，收率：24.8％)。
MS m/z(ESI):531.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.98-7.96(m,1H),7.88-7.80(m,3H),7.75-7.67(m,2H),7.59-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.44(m,1H),7.28-7.26(m,1H),5.30(s,2H),2.71(s,3H)。
实施例13：7-(3-(二氟甲氧基)-5-氟苯基)-3-乙基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物13)的制备
Figure PCTCN2019094579-appb-000045
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为乙胺，得到标题化合物(73mg，收率：25.7％)。
MS m/z(ESI):545.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.98-7.97(m,1H),7.89-7.82(m,2H),7.77-7.75(m,1H),7.74-7.66(m,2H),7.60-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.44(m,1H),7.29-7.26(m,1H),5.32(s,2H),3.22-3.20(m,2H),0.98-0.94(m,3H)。
实施例14：7-(3-(二氟甲氧基)-5-氟苯基)-3-异丙基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物14)的制备
Figure PCTCN2019094579-appb-000046
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为异丙胺，得到标题化合物(64mg，收率：23.9％)。
MS m/z(ESI):559.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.97-7.95(m,1H),7.91-7.84(m,2H),7.78-7.71(m,3H),7.56-7.53(m,1H),7.47(t,J＝72.8Hz,1H),7.42-7.40(m,1H),7.28-7.26(m,1H),5.23(s,2H),4.41-4.34(m,1H),1.08(d,J＝8.0Hz,6H)。
实施例15：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙腈(化合物15)的制备
Figure PCTCN2019094579-appb-000047
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为3-氨基丙腈，得到标题化合物(62mg，收率：25.9％)。
MS m/z(ESI):570.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.98-7.95(m,2H),7.83-7.80(m,2H),7.64-7.62(m,1H),7.54-7.51(m,2H),7.25-7.21(m,2H),6.99-6.96(m,1H),6.61(t,J＝72.8Hz,1H),5.39(s,2H),3.49(t,J＝6.4Hz,2H),2.65(t,J＝6.4Hz,2H)。
实施例16：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-(甲基磺酰基)乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物16)的制备
Figure PCTCN2019094579-appb-000048
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为2-(甲磺酰基)乙胺，得到标题化合物(63mg，收率：25.4％)。
MS m/z(ESI):623.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.10-8.07(m,1H),7.99-7.97(m,1H),7.90-7.88(m,1H),7.84-7.82(m,2H),7.75-7.73(m,2H),7.61-7.58(m,1H),7.47(t,J＝72.8Hz,1H),7.48-7.46(m,1H),7.30-7.26(m,1H),5.36(s,2H),3.59(t,J＝8.0Hz,2H),3.29(t,J＝8.0Hz,2H),3.03(s,3H)。
实施例17：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-羟基-2-甲基丙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物17)的制备
Figure PCTCN2019094579-appb-000049
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为1-氨基-2-甲基-2-丙醇，得到标题化合物(87mg，收率：27.5％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.06(m,1H),7.99-7.98(m,1H),7.90-7.83(m,2H),7.73-7.71(m,3H),7.59-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.36(s,2H),4.63(s,1H),3.11(s,2H),0.99(s,6H)。
实施例18：2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基乙酰胺(化合物18)的制备
Figure PCTCN2019094579-appb-000050
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为N,N-二甲基甘氨酰胺，得到标题化合物(64mg，收率：26.4％)。
MS m/z(ESI):602.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),8.03-7.99(m,2H),7.89-7.85(m,1H),7.82-7.79(m,1H),7.73-7.66(m,2H),7.60-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.45(m,1H),7.30-7.26(m,1H),5.33(s,2H),4.14(s,2H),2.93(s,3H),2.81(s,3H)。
实施例19：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基丙酰胺(化合物19)的制备
Figure PCTCN2019094579-appb-000051
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为3-氨基-N,N-二甲基丙酰胺，得到标题化合物(58mg，收率：26.8％)。
MS m/z(ESI):616.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.09-8.07(m,1H),7.99-7.96(m,1H),7.89-7.86(m,1H),7.83-7.81(m,1H),7.76-7.71(m,3H),7.60-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),5.32(s,2H),3.34-3.31(m,2H),2.90(s,3H),2.81(s,3H),2.51-2.47(m,2H)。
实施例20：4-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基丁酰胺(化合物20)的制备
Figure PCTCN2019094579-appb-000052
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为4-氨基-N,N-二甲基丁酰胺盐酸盐，得到标题化合物(58mg，收率：26.4％)。
MS m/z(ESI):630.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.99-7.97(m,1H),7.89-7.82(m,2H),7.75-7.69(m,3H),7.59-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.43(m,1H),7.29-7.26(m,1H),5.33(s,2H),3.20-3.16(m,2H),2.90(s,3H),2.77(s,3H),3.23-3.19(m,2H),1.66-1.59(m,2H)。
实施例21：2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙酸甲酯(化合物21)的制备
Figure PCTCN2019094579-appb-000053
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为甘氨酸甲酯盐酸盐，得到标题化合物(82mg，收率：29.3％)。
MS m/z(ESI):589.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),8.02-8.00(m,1H),7.92-7.88(m,2H),7.84-7.82(m,1H),7.73-7.70(m,2H),7.60-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.45(m,1H),7.30-7.27(m,1H),5.44(s,2H),4.06(s,2H),3.64(s,3H)。
实施例22：2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙酸(化合物22)的制备
Figure PCTCN2019094579-appb-000054
采用实施例2合成路线，将原料3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)丙酸甲酯替换为2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙酸甲酯，得到标题化合物(72mg，收率：36.2％)。
MS m/z(ESI):575.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.06-8.05(m,1H),7.99-7.97(m,1H),7.89-7.86(m,2H),7.83-7.81(m,1H),7.75-7.69(m,2H),7.59-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),5.36(s,2H),3.82(s,2H)。
实施例23：N-(2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-乙基)甲基磺酰胺(化合物23)的制备
Figure PCTCN2019094579-appb-000055
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为N-(2-氨基乙基)甲磺酰胺盐酸盐，得到标题化合物(47mg，收率：24.3％)。
MS m/z(ESI):638.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.07(m,1H),7.99-7.97(m,1H),7.90-7.82(m,2H),7.76-7.75(m,2H),7.60-7.58(m,1H),7.48-7.46(m,1H),7.47(t,J＝72.8Hz,1H),7.29-7.27(m,1H),7.14-7.11(m,1H),5.36(s,2H),3.29-3.26(m,2H),3.05-3.03(m,2H),2.90(s,3H)。
实施例24：2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N-甲基乙基磺酰胺(化合物24)的制备
Figure PCTCN2019094579-appb-000056
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为2-氨基-N-甲基乙烷磺酰胺盐酸盐，得到 标题化合物(72mg，收率：26.8％)。
MS m/z(ESI):638.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.10-8.08(m,1H),7.99-7.98(m,1H),7.90-7.83(m,2H),7.76-7.73(m,2H),7.60-7.58(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),7.08-7.04(m,1H),5.36(s,2H),3.51-3.47(m,2H),3.19-3.17(m,2H),2.58-2.56(m,3H)。
实施例25：2-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-N,N-二甲基乙基磺酰胺(化合物25)的制备
Figure PCTCN2019094579-appb-000057
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为2-氨基-N,N-二甲基乙基磺酰胺，得到标题化合物(61mg，收率：26.4％)。
MS m/z(ESI):652.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.96-7.94(m,2H),7.82-7.79(m,2H),7.62-7.59(m,1H),7.54-7.50(m,2H),7.25-7.21(m,2H),7.00-6.96(m,1H),6.61(t,J＝72.8Hz,1H),5.34(s,2H),3.60(t,J＝5.6Hz,2H),3.11(t,J＝5.6Hz,2H),2.85(s,6H)。
实施例26：7-(3-(二氟甲氧基)-5-氟苯基)-3-(氧杂环丁烷-3-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物26)的制备
Figure PCTCN2019094579-appb-000058
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为3-氧杂环丁胺，得到标题化合物(65mg，收率：27.3％)。
MS m/z(ESI):573.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.09-8.07(m,1H),8.00-7.98(m,1H),7.91-7.85(m,2H),7.78-7.76(m, 2H),7.59-7.56(m,2H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.39(s,2H),4.97-4.90(m,1H),4.66-4.59(m,4H)。
实施例27：(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(四氢呋喃-3-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物27)的制备
Figure PCTCN2019094579-appb-000059
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(R)-3-氨基四氢呋喃，得到标题化合物(61mg，收率：27.3％)。
MS m/z(ESI):587.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.07(m,1H),7.95-7.87(m,3H),7.76-7.73(m,2H),7.68-7.65(m,1H),7.57-7.54(m,1H),7.46(t,J＝72.8Hz,1H),7.45-7.43(m,1H),7.29-7.26(m,1H),5.27(s,2H),4.68-4.66(m,1H),4.00-3.94(m,1H),3.68-3.62(m,3H),2.17-2.10(m,1H),1.93-1.85(m,1H)。
实施例28：(S)-7-(3-(二氟甲氧基)-5-氟苯基)-3-(四氢呋喃-3-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物28)的制备
Figure PCTCN2019094579-appb-000060
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(S)-3-氨基四氢呋喃，得到标题化合物(65mg，收率：28.7％)。
MS m/z(ESI):587.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.09-8.07(m,1H),7.96-7.87(m,3H),7.76-7.73(m,2H),7.68-7.65(m,1H),7.57-7.54(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.43(m,1H),7.29-7.26(m,1H),5.27(s,2H),4.68-4.65(m,1H),4.00-3.94(m,1H),3.68-3.63(m,3H),2.17-2.10(m,1H),1.93-1.86(m,1H)。
实施例29：7-(3-(二氟甲氧基)-5-氟苯基)-3-(四氢-2H-吡喃-4-基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物29)的制备
Figure PCTCN2019094579-appb-000061
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为4-氨基四氢吡喃，得到标题化合物(69mg，收率：28.7％)。
MS m/z(ESI):601.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.94-7.85(m,3H),7.79-7.74(m,2H),7.72-7.70(m,1H),7.55-7.53(m,1H),7.46(t,J＝72.8Hz,1H),7.43-7.41(m,1H),7.29-7.26(m,1H),5.26(s,2H),4.26-4.19(m,1H),3.93-3.90(m,2H),3.37-3.32(m,2H),1.84-1.76(m,2H),1.39-1.36(m,2H)。
实施例30：7-(3-(二氟甲氧基)-5-氟苯基)-3-(氧杂环丁烷-2-基甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物30)的制备
Figure PCTCN2019094579-appb-000062
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为2-氨甲基氧杂环丁烷，得到标题化合物(86mg，收率：28.4％)。
MS m/z(ESI):587.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),8.01-7.97(m,1H),7.90-7.84(m,3H),7.74-7.70(m,2H),7.59-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.48-7.46(m,1H),7.29-7.26(m,1H),5.44-5.34(m,2H),4.74-4.72(m,1H),4.53-4.43(m,2H),3.51-3.41(m,2H),2.54-2.51(m,1H),2.35-2.26(m,1H)。
实施例31：(R)-7-(3-(二氟甲氧基)-5-氟苯基)-3-((四氢呋喃-2-基)甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物31)的制备
Figure PCTCN2019094579-appb-000063
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(R)-(+)-四氢糠胺，得到标题化合物(75mg，收率：28.9％)。
MS m/z(ESI):601.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.06-8.04(m,1H),7.98-7.96(m,1H),7.89-7.82(m,3H),7.75-7.72(m,2H),7.58-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.42(m,1H),7.28-7.26(m,1H),5.37-5.29(m,2H),3.86-3.77(m,3H),3.39-3.36(m,1H),3.13-3.08(m,1H),1.88-1.73(m,3H),1.46-1.41(m,1H)。
实施例32：(S)-7-(3-(二氟甲氧基)-5-氟苯基)-3-((四氢呋喃-2-基)甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物32)的制备
Figure PCTCN2019094579-appb-000064
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为(S)-(+)-四氢糠胺，得到标题化合物(75mg，收率：28.9％)。
MS m/z(ESI):601.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.06-8.05(m,1H),7.98-7.96(m,1H),7.89-7.82(m,3H),7.75-7.71(m,2H),7.58-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.45-7.43(m,1H),7.28-7.26(m,1H),5.37-5.28(m,2H),3.86-3.77(m,3H),3.39-3.37(m,1H),3.14-3.07(m,1H),1.88-1.73(m,3H),1.46-1.40(m,1H)。
实施例33：7-(3-(二氟甲氧基)-5-氟苯基)-3-((四氢-2H-吡喃-2-基)甲基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物33)的制备
Figure PCTCN2019094579-appb-000065
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为2-氨基甲基四氢吡喃，得到标题化合物(69mg，收率：27.6％)。
MS m/z(ESI):615.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.06-8.04(m,1H),7.98-7.96(m,1H),7.88-7.71(m,5H),7.58-7.55(m,1H),7.47(t,J＝72.8Hz,1H),7.47-7.45(m,1H),7.29-7.26(m,1H),5.29(s,2H),3.88-3.85(m,1H),3.30-3.10(m,4H),1.75-1.73(m,1H),1.48-1.43(m,4H),1.14-1.11(m,1H)。
实施例34：7-(2-氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物34)的制备
Figure PCTCN2019094579-appb-000066
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氟苯硼酸，得到标题化合物(72mg，收率：28.9％)。
MS m/z(ESI):509.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.98-7.93(m,2H),7.86-7.84(m,1H),7.78-7.76(m,1H),7.60-7.39(m,5H),7.31-7.28(m,1H),7.26-7.20(m,1H),5.28(s,2H),3.50-3.43(m,4H),3.33(s,3H)。
实施例35：7-(3-氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物35)的制备
Figure PCTCN2019094579-appb-000067
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氟苯硼酸，得到标题化合物(69mg，收率：28.6％)。
MS m/z(ESI):509.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.97-7.94(m,1H),7.86-7.80(m,3H),7.77-7.71(m,2H),7.65-7.58(m,3H),7.35-7.31(m,1H),5.31(s,2H),3.40-3.36(m,4H),3.26(s,3H)。
实施例36：7-(2-二氟甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物36)的制备
Figure PCTCN2019094579-appb-000068
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-二氟甲氧基苯硼酸，得到标题化合物(78mg，收率：25.6％)。
MS m/z(ESI):557.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.06-8.04(m,1H),7.86-7.80(m,3H),7.76-7.72(m,2H),7.59-7.54(m,3H),7.45-7.39(m,2H),7.25(t,J＝72.8Hz,1H),5.32(s,2H),3.44-3.41(m,4H),3.28(s,3H)。
实施例37：7-(3-二氟甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物37)的制备
Figure PCTCN2019094579-appb-000069
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-二氟甲氧基苯硼酸，得到标题化合物(72mg，收率：26.1％)。
MS m/z(ESI):557.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.96-7.94(m,1H),7.84-7.71(m,5H),7.68-7.57(m,3H),7.41(t,J＝72.8Hz,1H),7.32-7.30(m,1H),5.32(s,2H),3.44-3.40(m,4H),3.27(s,3H)。
实施例38：7-(4-二氟甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物38)的制备
Figure PCTCN2019094579-appb-000070
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为4-二氟甲氧基苯硼酸，得到标题化合物(82mg，收率：28.6％)。
MS m/z(ESI):557.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.97-7.94(m,2H),7.83-7.77(m,2H),7.70-7.68(m,2H),7.61-7.59(m,1H),7.52-7.47(m,2H),7.29-7.27(m,2H),6.59(t,J＝72.8Hz,1H),5.26(s,2H),3.47-3.40(m,4H),3.33(s,3H)。
实施例39：7-(2-甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物39)的制备
Figure PCTCN2019094579-appb-000071
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-甲氧基苯硼酸，得到标题化合物(78mg，收率：26.3％)。
MS m/z(ESI):521.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:8.05-8.03(m,1H),7.83-7.81(m,2H),7.77-7.73(m,3H),7.57-7.54(m,1H),7.47-7.43(m,1H),7.40-7.38(m,1H),7.21-7.19(m,1H),7.13-7.10(m,1H),5.31(s,2H),3.84(s,3H),3.43-3.41(m,4H),3.27(s,3H)。
实施例40：7-(3-甲氧基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物40)的制备
Figure PCTCN2019094579-appb-000072
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-甲氧基苯硼酸，得到标题化合物(82mg，收率：27.5％)。
MS m/z(ESI):521.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:8.01-7.99(m,1H),7.94-7.92(m,1H),7.85-7.83(m,1H),7.78-7.76(m,1H),7.64-7.61(m,1H),7.51-7.41(m,3H),7.29-7.27(m,1H),7.21-7.19(m,1H),7.00-6.98(m,1H),5.26(s,2H),3.91(s,3H),3.48-3.40(m,4H),3.33(s,3H)。
实施例41：7-(2-氰基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物41)的制备
Figure PCTCN2019094579-appb-000073
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氰基苯硼酸，得到标题化合物(75mg，收率：26.3％)。
MS m/z(ESI):516.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.06-8.04(m,2H),7.91-7.84(m,5H),7.75-7.67(m,4H),5.34(s,2H),3.44-3.41(m,4H),3.27(s,3H)。
实施例42：7-(3-氰基苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物42)的制备
Figure PCTCN2019094579-appb-000074
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氰基苯硼酸，得到标题化合物(64mg，收率：25.6％)。
MS m/z(ESI):516.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:8.01-7.99(m,2H),7.95-7.90(m,2H),7.83-7.74(m,3H),7.66-7.60(m,2H),7.53-7.48(m,2H),5.27(s,2H),3.48-3.39(m,4H),3.33(s,3H)。
实施例43：7-(2,3-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物43)的制备
Figure PCTCN2019094579-appb-000075
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2,3-二氟苯硼酸，得到标题化合物(81mg，收率：27.6％)。
MS m/z(ESI):527.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.86-7.80(m,3H),7.77-7.73(m,2H),7.70-7.67(m,1H),7.60-7.54(m,1H),7.48-7.39(m,2H),5.33(s,2H),3.44-3.39(m,4H),3.27(s,3H)。
实施例44：7-(2,5-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物44)的制备
Figure PCTCN2019094579-appb-000076
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2,5-二氟苯硼酸，得到标题化合物(78mg，收率：28.9％)。
MS m/z(ESI):527.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.87-7.68(m,6H),7.56-7.39(m,3H),5.32(s,2H),3.43-3.40(m,4H),3.27(s,3H)。
实施例45：7-(2,6-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物45)的制备
Figure PCTCN2019094579-appb-000077
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2,6-二氟苯硼酸，得到标题化合物(89mg，收率：26.8％)。
MS m/z(ESI):527.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.87-7.76(m,4H),7.66-7.56(m,3H),7.34-7.30(m,2H),5.34(s,2H),3.43-3.40(m,4H),3.28(s,3H)。
实施例46：7-(3,5-二氟苯基)-3-(2-甲氧乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物46)的制备
Figure PCTCN2019094579-appb-000078
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3,5-二氟苯硼酸，得到标题化合物(87mg，收率：28.6％)。
MS m/z(ESI):527.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.99-7.97(m,1H),7.89-7.86(m,1H),7.83-7.80(m,2H),7.76-7.70(m,2H),7.60-7.55(m,2H),7.42-7.36(m,1H),5.31(s,2H),3.39-3.36(m,4H),3.25(s,3H)。
实施例47：3-(2-甲氧基乙基)-7-(6-甲氧基吡啶-2-基)-1-(3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物47)的制备
Figure PCTCN2019094579-appb-000079
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为6-甲氧基吡啶-2-硼酸，得到标题化合物(75mg，收率：26.3％)。
MS m/z(ESI):522.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.42-8.40(m,1H),8.20-8.18(m,1H),8.07-8.05(m,1H),7.90-7.81(m,3H),7.74-7.71(m,3H),6.93-6.91(m,1H),5.32(s,2H),4.00(s,3H),3.40-3.38(m,4H),3.25(s,3H)。
实施例48：3-(2-甲氧基乙基)-7-(2-甲氧基吡啶-3-基)-1-(3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物48)的制备
Figure PCTCN2019094579-appb-000080
采用实施例5合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-甲氧基吡啶-3-硼酸，得到标题化合物(81mg，收率：27.3％)。
MS m/z(ESI):522.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.29-8.27(m,1H),8.06-8.04(m,1H),7.91-7.87(m,2H),7.83-7.73(m,4H),7.65-7.63(m,1H),7.20-7.17(m,1H),5.31(s,2H),3.95(s,3H),3.42-3.40(m,4H),3.27(s,3H)。
实施例49：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-氰基苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物49)的制备
Figure PCTCN2019094579-appb-000081
采用实施例5合成路线，将第四步原料3-三氟甲基苯磺酰氯替换为3-氰基苯磺酰氯，得到标题化合物(68mg，收率：27.2％)。
MS m/z(ESI):532.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.19-8.14(m,2H),7.96-7.94(m,1H),7.89-7.79(m,2H),7.72-7.65(m,2H),7.61-7.57(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.28(s,2H),3.43-3.40(m,4H),3.28(s,3H)。
实施例50：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-1-((3-甲氧基苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物50)的制备
Figure PCTCN2019094579-appb-000082
采用实施例5合成路线，将第四步原料3-三氟甲基苯磺酰氯替换为3-甲氧基苯磺酰氯，得到标题化合物(75mg，收率：27.8％)。
MS m/z(ESI):537.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:7.96-7.94(m,1H),7.85-7.83(m,2H),7.57-7.55(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.39(m,2H),7.28-7.25(m,1H),7.23-7.20(m,1H),7.09-7.07(m,1H),6.93-6.91(m,1H),5.25(s,2H),3.65(s,3H),3.38-3.35(m,4H),3.28(s,3H)。
实施例51：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物51)的制备
Figure PCTCN2019094579-appb-000083
第一步：7-溴-3-(2-甲氧乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮的制备
将2-氨基-4-溴-N-(2-甲氧乙基)苯甲酰胺(600mg,2.2mmol)、对甲苯磺酸(38mg,0.22mmol)溶于乙腈(8mL)中，加入2-甲氧基丙烯(5mL)后，室温反应12小时。将反应液减压浓缩后加入水(100mL)，乙酸乙酯萃取三次，合并有机相，饱和碳酸氢钠溶液返洗，无水硫酸钠干燥有机相，过滤并将滤液减压浓缩，得到本步的标题化合物(650mg，收率：94.5％)。
MS m/z(ESI):313.0[M+H] +。
第二步：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮的制备
将7-溴-3-(2-甲氧乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮(600mg,1.92mmol)、2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(993mg,3.45mmol)和碳酸钾(530mg,3.84mmol)溶于1,4-二氧六环(20mL)和水(4mL)的混合溶剂中，加入[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(156mg,0.19mmol)，氮气置换后，加热至80℃反应4小时。将反应液倾入水(100mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到本步的标题化合物(478mg，收率：63.2％)。
MS m/z(ESI):395.2[M+H] +。
第三步：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物51)的制备
将7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-甲氧基乙基)-2,2-二甲基-2,3-二氢喹唑啉-4(1H)-酮(400mg,1.01mmol)完全溶于吡啶(5mL)中，加入
Figure PCTCN2019094579-appb-000084
分子筛(200mg)，3-三氟甲基苯磺酰氯(1.24g,5.05mmol)，微波加热至100℃反应1小时。冷却至室温后，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(37mg，收率：6.1％)。
MS m/z(ESI):603.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.09-8.07(m,1H),7.98-7.94(m,2H),7.83-7.78(m,3H),7.62-7.60(m,1H),7.50-7.49(m,1H),7.48(t,J＝72.8Hz,1H),7.39-7.38(m,1H),7.28-7.25(m,1H),3.20-3.17(m,7H),2.11-2.07(m,3H),1.40-1.36(m,3H)。
实施例52：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物52)的制备
Figure PCTCN2019094579-appb-000085
第一步：3-(2-氨基-4-溴苯基甲酰基氨基)-2,2-二甲基丙酸乙酯的制备
将2-氨基-4-溴苯甲酸(5.0g,23.1mmol)、2,2-二甲基-3-氨基丙酸乙酯盐酸盐(4.7g,27.8mmol)和HATU(9.7g,25.5mmol)加入四氢呋喃(50mL)中，室温搅拌下缓慢加入DIPEA(15.0g,115.7mmol)后维持室温反应4小时。将反应液倾入水(250mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(7.23g，收率：94.9％)。
MS m/z(ESI):343.1[M+H] +。
第二步：3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(2-氨基-4-溴苯甲酰胺)-2,2-二甲基丙酸乙酯(3.35g,10.2mmol)和37％甲醛水溶液(826mg,10.2mmol)混溶于乙醇(30mL)中，加入氢氧化钠(570mg,14.3mmol)后，加热至60℃反应3小时。将反应液减压浓缩后加入水(150mL)，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经过硅胶柱层析纯化(洗脱剂：石油醚/乙酸乙酯＝5/1)得到本步的标题化合物(3.2g，收率：85.8％)。
MS m/z(ESI):355.1[M+H] +。
第三步：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.99mmol)和2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷(369mg,1.28mmol)溶于1,4-二氧六环(4mL)和水(1mL)的混合溶剂中，加入碳酸钾(272mg,1.97mmol)和[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(81mg,98μmol)，氮气置换后加热至80℃反应4小时。将反应液倾入水(150mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(350mg，收率：81.4％)。
MS m/z(ESI):437.2[M+H] +
第四步：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.80mmol)完全溶于吡啶(4mL)中，加入3-三氟甲基苯磺酰氯(588mg,2.41mmol)，加热至80℃反应2小时。冷却至室温后，减压浓缩，剩余物加入水(150mL)，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩得到本步的标题化合物(420mg，收率：81.2％)。
MS m/z(ESI):645.1[M+H] +。
第五步：3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物52)的制备
将3-(7-(3-(二氟甲氧基)-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(200mg,0.31mmol)溶于乙醇(3mL)和水(3mL)的混合溶剂中，加入氢氧化钠(124mg,3.10mmol)，升温于80℃搅拌反应1小时。冷却至室温后减压浓缩除去乙醇，剩余物加入水(100mL)，用2N盐酸调节pH＝2，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(80mg，收率：41.0％)。
MS m/z(ESI):617.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.98-7.97(m,1H),7.90-7.87(m,1H),7.81-7.80(m,1H),7.76-7.72(m,3H),7.58-7.56(m,1H),7.47(t,J＝72.8Hz,1H),7.46-7.45(m,1H),7.29-7.26(m,1H),5.33(s,2H),3.33-3.30(m,2H),1.02(s,6H)。
实施例53：3-(4-氧代-7-苯基-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物53)的制备
Figure PCTCN2019094579-appb-000086
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为苯硼酸，得到标题化合物(87mg，收率：28.9％)。
MS m/z(ESI):533.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:12.6(br,1H),8.08-8.06(m,1H),7.92-7.90(m,1H),7.83-7.70(m,7H),7.59-7.51(m,2H),7.51-7.47(m,1H),5.34(s,2H),3.47-3.45(m,2H),1.04(s,6H)。
实施例54：3-(7-(3-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物54)的制备
Figure PCTCN2019094579-appb-000087
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氟苯硼酸，得到标题化合物(72mg，收率：27.4％)。
MS m/z(ESI):551.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:12.6(br,1H),8.08-8.06(m,1H),7.95-7.93(m,1H),7.87-7.79(m,2H),7.76-7.58(m,6H),7.36-7.31(m,1H),5.33(s,2H),3.35-3.32(m,2H),1.04(s,6H)。
实施例55：3-(7-(3-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物55)的制备
Figure PCTCN2019094579-appb-000088
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-甲氧基苯硼酸，得到标题化合物(78mg，收率：28.3％)。
MS m/z(ESI):563.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.98-7.97(m,1H),7.91-7.89(m,1H),7.80-7.78(m,2H),7.65-7.63(m,1H),7.52-7.40(m,3H),7.25-7.23(m,1H),7.19-7.18(m,1H),7.00-6.98(m,1H),5.27(s,2H),3.89(s,3H),3.41(s, 2H),1.21(s,6H)。
实施例56：3-(7-(2-二氟甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物56)的制备
Figure PCTCN2019094579-appb-000089
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-二氟甲氧基苯硼酸，得到标题化合物(82mg，收率：29.3％)。
MS m/z(ESI):599.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.90-7.89(m,2H),7.79-7.76(m,2H),7.55-7.42(m,5H),7.36-7.30(m,2H),6.47(t,J＝72.8Hz,1H),5.28(s,2H),3.42(s,2H),1.19(s,6H)。
实施例57：3-(7-(2-氯-5-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物57)的制备
Figure PCTCN2019094579-appb-000090
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氯-5-氟苯硼酸，得到标题化合物(74mg，收率：26.2％)。
MS m/z(ESI):585.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:12.6(br,1H),8.08-8.06(m,1H),7.82-7.69(m,5H),7.66-7.64(m,1H),7.57-7.55(m,1H),7.42-7.38(m,2H),5.35(s,2H),3.38-3.35(m,2H),1.05(s,6H)。
实施例58：3-(7-(2-氯-6-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物58)的制备
Figure PCTCN2019094579-appb-000091
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氯-6-氟苯硼酸，得到标题化合物(83mg，收率：27.6％)。
MS m/z(ESI):585.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.06(m,1H),7.85-7.80(m,3H),7.67-7.66(m,1H),7.58-7.50(m,4H),7.45-7.42(m,1H),5.37(s,2H),3.39-3.37(m,2H),1.05(s,6H)。
实施例59：3-(7-(3-氯-2-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物59)的制备
Figure PCTCN2019094579-appb-000092
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为3-氯-2-甲氧基苯硼酸，得到标题化合物(72mg，收率：27.8％)。
MS m/z(ESI):597.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.08-8.07(m,1H),7.85-7.84(m,1H),7.81-7.76(m,3H),7.67-7.60(m,3H),7.45-7.43(m,1H),7.34-7.30(m,1H),5.34(s,2H),3.58(s,3H),3.36-3.34(m,2H),1.03(s,6H)。
实施例60：3-(7-(2-氯-3-氟苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物60)的制备
Figure PCTCN2019094579-appb-000093
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氯-3-氟苯硼酸，得到标题化合物(87mg，收率：26.3％)。
MS m/z(ESI):585.1[M+H] +
1H-NMR(400MHz,CDCl 3)δ:7.94-7.92(m,1H),7.86-7.85(m,1H),7.81-7.77(m,2H),7.58-7.47(m,3H),7.38-7.32(m,1H),7.25-7.22(m,1H),7.19-7.17(m,1H),5.29(s,2H),3.46(s,2H),1.23(s,6H)。
实施例61：3-(7-(2-氟-3-甲基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物61)的制备
Figure PCTCN2019094579-appb-000094
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为2-氟-3-甲基苯硼酸，得到标题化合物(75mg，收率：27.2％)。
MS m/z(ESI):565.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:12.6(br,1H),8.08-8.06(m,1H),7.81-7.73(m,4H),7.67-7.64(m,2H),7.43-7.40(m,2H),7.29-7.25(m,1H),5.35(s,2H),3.36-3.35(m,2H),2.35(s,3H),1.05(s,6H)。
实施例62：3-(7-(6-甲基吡啶-2-基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物62)的制备
Figure PCTCN2019094579-appb-000095
采用实施例52合成路线，将第三步原料2-(3-(二氟甲氧基)-5-氟苯基)-4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷替换为6-甲基吡啶-2硼酸，得到标题化合物(75mg，收率：27.1％)。
MS m/z(ESI):548.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.38-8.37(m,1H),8.20-8.18(m,1H),8.08-8.06(m,1H),7.92-7.81(m,3H),7.75-7.66(m,3H),7.35-7.34(m,1H),5.33(s,2H),3.38-3.35(m,2H),2.59(s,3H),1.02(s,6H)。
实施例63：3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物63)的制备
Figure PCTCN2019094579-appb-000096
第一步：3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-溴-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.99mmol)和3-氯-5-甲氧基苯基硼酸(239mg,1.28mmol)溶于1,4-二氧六环(4mL)和水(1mL)的混合溶剂中，加入碳酸钾(272mg,1.97mmol)和[1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(81mg,98μmol)，氮气置换后加热至80℃反应4小时。将反应液倾入水(150mL)中，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，得到本步的标题化合物(362mg，收率：87.7％)。
MS m/z(ESI):417.2[M+H] +。
第二步：3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯的制备
将3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸乙酯(350mg,0.84mmol)完全溶于吡啶(4mL)中，加入3-三氟甲基苯磺酰氯(616mg,2.52mmol)，加热至80℃反应2小时。冷却至室温后，减压浓缩，剩余物加入水(150mL)，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩得到本步的标题化合物(458mg，收率：87.2％)。
MS m/z(ESI):625.1[M+H] +。
第三步：3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲基丙酸(化合物63)的制备
将3-(7-(3-氯-5-甲氧基苯基)-4-氧代-1-((3-(三氟甲基)苯基)磺酰基)-1,2-二氢喹唑啉-3(4H)-基)-2,2-二甲 基丙酸乙酯(200mg,0.32mmol)溶于乙醇(3mL)和水(3mL)的混合溶剂中，加入氢氧化钠(128mg,3.20mmol)，升温于80℃搅拌反应1小时。冷却至室温后减压浓缩除去乙醇，剩余物加入水(100mL)，用2N盐酸调节pH＝2，乙酸乙酯萃取三次，合并有机相，无水硫酸钠干燥，过滤并将滤液减压浓缩，浓缩物经制备高效液相色谱仪纯化得到标题化合物(75mg，收率：39.3％)。
MS m/z(ESI):597.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.33-8.31(m,1H),8.08-8.06(m,1H),7.90-7.84(m,2H),7.78-7.65(m,3H),7.39-7.37(m,1H),7.26-7.24(m,1H),7.17-7.15(m,1H),5.30(s,2H),3.89(s,3H),3.30-3.28(m,2H),0.99(s,6H)。
实施例64：7-(3-(二氟甲氧基)-5-氟苯基)-3-(2-吗啉基乙基)-1-((3-(三氟甲基)苯基)磺酰基)-2,3-二氢喹唑啉-4(1H)-酮(化合物64)的制备
Figure PCTCN2019094579-appb-000097
采用实施例5合成路线，将第一步原料2-甲氧基乙胺替换为 N-(2-氨基乙基)吗啉，得到标题化合物(11mg，收率：20.3％)。
MS m/z(ESI):630.1[M+H] +
1H-NMR(400MHz,DMSO-d 6)δ:8.07-8.05(m,1H),7.97-7.96(m,1H),7.88-7.81(m,3H),7.74-7.72(m,2H),7.58-7.56(m,1H),7.47(t,J＝72Hz,1H),7.46-7.44(m,1H),7.29-7.26(m,1H),5.34(s,2H),3.54-3.51(m,4H),3.31-3.28(m,2H),2.38-2.32(m,6H)。
生物学评价：
测试例1RORγ-LBD TR-FRET实验
一、实验材料及仪器
1.RORγ-LBD(辉源生物)
2.生物素-SRC1(PerkinElmer)
3.LANCE Eu-抗-6×His抗体(PerkinElmer)
4.SureLight Allophycocyanin-Streptavidin(PerkinElmer)
5.酶标仪(BMG Labtech)
二、实验方法
溶液配制：配制反应缓冲液(25mM HEPES，pH 7.0，100Mm NaCl，0.01％Tween 20，0.2％BSA，5mM  DTT)。以反应缓冲液配制含1nM LANCE Eu-抗-6×His抗体的溶液A1，含1nM LANCE Eu-抗-6×His抗体和15nM RORγ-LBD的溶液A2，以及含200nM生物素-SRC1和15nM Allophycocyanin-Streptavidin的溶液B，均置于冰上待用。
以DMSO稀释化合物，5μM起始，4倍稀释，10个浓度点。384孔板中的待测化合物孔加入0.25μl稀释后化合物、15μl溶液A2、以及10μl溶液B；阴性对照孔加入0.25μl DMSO、15μl溶液A1、以及10μl溶液B；溶剂对照孔加入0.25μl DMSO、15μl溶液A2、以及10μl溶液B。封口胶带封板，震荡2分钟混匀反应液。将384孔板置于4℃过夜。第2天取出384孔板至室温平衡1小时，离心1分钟。酶标仪读板(检测波长665nm/615nm)。
数据处理：化合物激活率＝(FI比值 化合物-FI比值 溶剂对照)/(FI比值 溶剂对照-FI比值 阴性对照)*100％，FI比值表示酶标仪读出荧光值(665nm)与酶标仪读出荧光值(615nm)的比值；由GraphPad Prism软件计算EC 50值。最大激活率是指：由上述化合物激活率公式得到的曲线处于上平台期时对应浓度点的激活率；所述最大激活率大于0时，表明待测化合物对RORγ具有激动作用。
本发明的待测化合物对RORγ的激动活性见表1。
表1本发明化合物对RORγ的激动活性
化合物编号 EC 50(nM) 最大激活率
1 2.98 89.2％
5 1.5 80.8％
6 3.7 62.1％
7 5.4 67.6％
8 2.5 69.7％
9 4.0 70.3％
10 3.5 79.9％
11 8.9 85.6％
12 0.45 71.6％
13 0.91 75.5％
14 0.19 95.3％
15 2.0 110.4％
16 5.4 123.1％
17 0.3 73.9％
18 0.64 86.4％
19 0.4 105.1％
20 1.4 89.3％
21 0.34 104.5％
22 10.6 73.7％
23 12.8 113.5％
24 0.07 97.9％
25 4.3 106.8％
26 9.5 73.6％
27 0.31 96.4％
28 5.1 66.0％
29 2.4 74.5％
30 6.0 67.2％
31 3.7 61.9％
32 3.4 61.0％
33 7.6 81.7％
34 1.4 72.8％
35 3.6 45.4％
36 4.5 56.0％
37 4.0 47.9％
38 9.0 54.6％
39 1.3 46.0％
40 2.6 76.4％
42 10.3 53.4％
43 7.6 53.1％
44 2.2 75.8％
45 3.2 77.6％
46 1.3 43.2％
47 7.2 51.0％
48 9.7 52.7％
49 10.5 62.3％
50 15.2 71.9％
51 1.3 102.3％
52 6.3 105.7％
53 2.8 60.2％
54 17.5 64.5％
55 2.1 71.1％
56 10.4 70.0％
57 2.3 99.1％
63 8.7 92.8％
64 5.7 109.0％
由此可见，本发明化合物对RORγ具有明显的激动作用，具有例如小于100nM、优选小于20nM、更优选小于10nM的EC 50，最大激活率均在40％以上。
测试例2RORγ-荧光素酶报告基因实验
一、实验材料及仪器
1.质粒pcDNA3.1(GAL4DBD/RORγLBD)，pGL4.35(luc2P/9×GAL4UAS/Hygro)南京科佰生物构建
2.Lipofectamine 3000(Invitrogen)
3.Bright-Glo TM(Promega)
4.乌苏酸(Cayman Chemical)
5.酶标仪(BMG Labtech)
6. 293T细胞(购自ATCC)
7.待测化合物(以DMSO配制为10mM储备液)
二、实验方法
293T细胞以DMEM高糖培养基(含10％FBS)培养于T25细胞培养瓶中，生长至融合度80％左右时，按Lipofectamine 3000说明书制备包载质粒的脂质体。将脂质体与一定体积的DMEM高糖培养基(含10％FBS)混合，去除T25培养瓶中原培养基，加入上述脂质体与DMEM高糖培养基的混合液转染293T细胞。转染后24h，消化细胞并计数。以DMEM高糖培养基(含10％FBS，2μM乌苏酸)稀释细胞至一定浓度，均匀铺至96孔培养板，每孔含细胞约10 5个。以DMEM高糖培养基(含10％FBS，2μM乌苏酸) 稀释待测化合物储备液以及溶剂对照(DMSO)，100μM起始，3倍稀释，10个浓度点。将稀释后化合物和溶剂对照分别加入96孔细胞培养板的实验孔和溶剂对照孔中。震荡细胞培养板2分钟使化合物与培养基充分混合，于37℃，5％CO 2孵箱中继续培养24小时。取出96孔细胞培养板至室温平衡10min，按照说明书加入Bright-Glo TM，震荡5分钟充分混匀。快速转移混合液至检测板。酶标仪检测发光强度。
数据处理：激活率＝实验孔发光值/溶剂对照孔平均发光值*100％。溶剂对照孔平均发光值定义为100％，使用Graphpad Prism 5软件进行数据分析与作图，以激活率与化合物浓度的对数经四参数拟合曲线计算EC 50值；最大激活率为所述拟合曲线处于上平台期时对应浓度点的激活率；所述最大激活率大于100％时，表明待测化合物对RORγ具有激动作用。
本发明化合物在细胞中对RORγ的激动活性见表2。
表2本发明化合物对RORγ的激动活性
化合物编号 EC 50(nM) 最大激活率
1 553 319.7％
5 810 703.2％
6 436 433.9％
7 304 342.1％
9 702 409.6％
13 610 440.0％
15 769 542.5％
16 237 335.5％
17 209 533.7％
18 787 504.6％
20 607 504.7％
21 345 450.4％
23 649 304.1％
25 752 410.1％
26 374 321.6％
27 230 530.1％
29 150 377.1％
30 409 403.0％
31 270 387.8％
32 228 446.6％
33 333 446.2％
34 351 345.0％
36 628 402.4％
37 267 379.2％
39 277 319.2％
40 176 329.0％
43 651 396.9％
44 338 323.0％
45 451 380.1％
46 470 405.8％
52 267 449.3％
63 233 518.7％
由此可见，本发明化合物在细胞中对RORγ具有明显的激动作用，具有例如小于1μM的EC 50以及大于300％的最大激活率。

Claims (12)

  1. 式I化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
    Figure PCTCN2019094579-appb-100001
    环A 1选自苯基和5-10元杂芳基；
    环A 2选自苯基、5-6元杂芳基和3-6元杂环基；
    L为共价键或选自-C(R a)(R b)-和-C(R a)(R b)-C(R a)(R b)-；
    R 1选自C 1-6烷基和4-10元杂环基；且可任选地被0、1、2或3个独立的选自下组的取代基所取代，该组取代基选自：卤素、-CN、-OH、-CO 2R 5a、-OR 6、-S(O) 2-R 6、-C(O)-N(R 5a)(R 5b)、-N(R 5a)C(O)R 6、-S(O) 2-N(R 5a)(R 5b)、-N(R 5a)S(O) 2R 6、4-10元杂环基、6-10元芳基和5-10元杂芳基；
    每个R 2各自独立地选自卤素、氰基、羟基、C 1-6烷基、C 3-6环烷基、C 1-6卤代烷基、C 1-6烷氧基、C 1-6卤代烷氧基和-O-C 3-6环烷基；
    每个R 3各自独立地选自卤素、氰基、羟基、C 1-6烷基、C 1-6卤代烷基、C 3-6环烷基、C 1-6烷氧基、C 1-6卤代烷氧基和-S(O) 2-R 6；
    每个R 4各自独立地选自卤素、氰基、C 1-6烷基和C 1-6烷氧基；
    R 5a和R 5b各自独立地选自氢和C 1-6烷基；
    或者R 5a、R 5b连同其相连的氮原子共同形成3-7元杂环基；
    R 6选自C 1-6烷基和C 3-6环烷基；
    每个R a和R b各自独立地选自氢和C 1-6烷基；
    m为0、1、2或3；
    n为0、1、2或3；
    p为0、1或2。
  2. 根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中所述化合物具有式II-A或II-B的结构：
    Figure PCTCN2019094579-appb-100002
    其中
    每个R a和R b各自独立地选自氢和C 1-4烷基；
    环A 1、环A 2、R 1、R 2、R 3、m和n定义如权利要求1中所定义。
  3. 根据权利要求1-2所述的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：R 1选自C 1-4烷基和4-6元杂环基；且可任选地被0、1或2个独立的选自下组的取代基所取代，该组取代基包括：卤素、-CN、-OH、-CO 2R 5a、-OR 6、-S(O) 2-R 6、-C(O)-N(R 5a)(R 5b)、-N(R 5a)C(O)R 6、-S(O) 2-N(R 5a)(R 5b)、-N(R 5a)S(O) 2R 6、4-6元杂环基、6-10元芳基和5-10元杂芳基；
    更优选R 1选自C 1-4烷基、C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-CO 2R 5a、-C 1-4亚烷基-O-R 6、-C 1-4亚烷基-S(O) 2-R 6、-C 1-4亚烷基-C(O)-N(R 5a)(R 5b)、-C 1-4亚烷基-N(R 5a)C(O)R 6、-C 1-4亚烷基-S(O) 2-N(R 5a)(R 5b)和-C 1-4亚烷基-N(R 5a)S(O) 2R 6、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C 1-4亚烷基-氧杂环丁烷、-C 1-4亚烷基-四氢呋喃、-C 1-4亚烷基-四氢吡喃和-C 1-4亚烷基-吗啉；
    R 5a和R 5b各自独立地选自氢和C 1-4烷基；
    或者R 5a、R 5b连同其相连的氮原子共同形成4-6元杂环基；
    R 6选自C 1-4烷基和C 3-6环烷基；
    优选地，R 1选自C 1-4烷基、C 1-4卤代烷基、-C 1-4亚烷基-CN、-C 1-4亚烷基-OH、-C 1-4亚烷基-C(O)OH、-C 1-4亚烷基-C(O)O-C 1-4烷基、-C 1-4亚烷基-O-C 1-4烷基、-C 1-4亚烷基-O-C 3-6环烷基、-C 1-4亚烷基-S(O) 2-C 1-4烷基、-C 1-4亚烷基-C(O)-NH-C 1-4烷基、-C 1-4亚烷基-C(O)-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-NH-C(O)-C 1-4烷基、-C 1-4亚烷基-S(O) 2-N(C 1-4烷基)(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH-(C 1-4烷基)、-C 1-4亚烷基-S(O) 2-NH 2、-C 1-4亚烷基-NH-S(O) 2-C 1-4烷基、氧杂环丁烷基、四氢呋喃基、四氢-2H-吡喃基、-C 1-3亚烷基-氧杂环丁烷、 -C 1-3亚烷基-四氢呋喃、-C 1-3亚烷基-四氢吡喃和-C 1-3亚烷基-吗啉；
    更优选地，R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2-CN、-CH 2CH 2CH 2-CN、-CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2C(O)OH、-CH 2CH 2C(O)OH、-CH 2C(CH 3) 2C(O)OH、-CH 2C(O)O-CH 3、-CH 2CH 2C(O)O-CH 3、-CH 2C(CH 3) 2C(O)O-CH 3、-CH 2CH 2-O-CH 3、-CH 2CH(CH 3)-O-CH 3、-CH 2CH 2CH 2-O-CH 3、-CH 2CH 2-O-CH 2CH 3、-CH(CH 3)CH 2-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2、-CH 2CH 2-NH-S(O) 2-CH 3、
    Figure PCTCN2019094579-appb-100003
    Figure PCTCN2019094579-appb-100004
  4. 根据权利要求1-3所述的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
    环A 1选自苯基和5-10元杂芳基；R 2选自卤素、氰基、羟基、C 1-4烷基、C 3-6环烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-O-C 3-6环烷基；
    优选地，环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；R 2选自卤素、氰基、C 3-6环烷基、C 1-4卤代烷基和C 1-4卤代烷氧基；
    更优选地，环A 1选自苯基和吡啶基；R 2选自卤素、氰基、C 1-4烷基、C 3-6环烷基、C 1-4烷氧基、C 1-4卤代烷基和C 1-4卤代烷氧基；
    特别优选地，环A 1选自苯基和吡啶基；R 2选自氟、氯、氰基、甲基、甲氧基和二氟甲氧基。
  5. 根据权利要求1-4所述的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中：
    环A 2选自苯基和5-6元杂芳基；R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 3-6环烷基、C 1-4烷氧基、C 1-4卤代烷氧基和-S(O) 2-C 1-4烷基；
    优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基；R 3选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 1-4卤代烷氧基和-S(O) 2-C 1-4烷基；
    特别优选地，环A 2选自苯基、吡啶基、异噁唑基和吡唑基；R 3选自三氟甲基、甲基、氰基、氟和甲磺酰基。
  6. 根据权利要求1-5所述的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其具有式II-A或II-B所示的结构，其中：
    环A 1选自苯基、吡啶基、异噁唑基、吡唑基和咪唑并[1,2-a]吡啶基；
    环A 2选自苯基、吡啶基、异噁唑基和吡唑基；
    R a和R b都是氢；
    R 1选自-CH 3、-CH 2CH 3、-CH(CH 3) 2、-CH 2CH 2CH 2F、-CH 2CH 2-CN、-CH 2CH 2CH 2-CN、 -CH 2CH 2C(CH 3) 2-CN、-CH 2C(CH 3) 2-OH、-CH 2CH 2C(CH 3) 2-OH、-CH 2C(O)OH、-CH 2CH 2C(O)OH、-CH 2C(CH 3) 2C(O)OH、-CH 2C(O)O-CH 3、-CH 2CH 2C(O)O-CH 3、-CH 2C(CH 3) 2C(O)O-CH 3、-CH 2CH 2-O-CH 3、-CH 2CH(CH 3)-O-CH 3、-CH 2CH 2CH 2-O-CH 3、-CH 2CH 2-O-CH 2CH 3、-CH(CH 3)CH 2-O-CH 3、-CH 2CH 2-S(O) 2-CH 3、-CH 2CH 2-C(O)-NH-CH 3、-CH 2CH 2CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-C(O)-N(CH 3) 2、-CH 2-C(O)-N(CH 3) 2、-CH 2CH 2-NH-C(O)-CH 3、-CH 2CH 2-S(O) 2-N(CH 3) 2、-CH 2CH 2-S(O) 2-NHCH 3、-CH 2CH 2-S(O) 2-NH 2、-CH 2CH 2-NH-S(O) 2-CH 3、
    Figure PCTCN2019094579-appb-100005
    Figure PCTCN2019094579-appb-100006
    每个R 2各自独立地选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基、C 1-4烷氧基、C 1-4卤代烷氧基；
    每个R 3各自独立地选自卤素、氰基、C 1-4烷基、C 1-4卤代烷基和-S(O) 2-C 1-4烷基；
    m为0、1、2或3；
    n为0、1、2或3。
  7. 根据权利要求1-6中任一项所述的化合物或其药学上可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，其中所述化合物选自：
    Figure PCTCN2019094579-appb-100007
    Figure PCTCN2019094579-appb-100008
    Figure PCTCN2019094579-appb-100009
  8. 药物组合物，其包含预防或治疗有效量的权利要求1-7中任一项的化合物或其药学可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，以及任选的一种或多种药学上可接受的赋形剂。
  9. 药物制剂，其包含权利要求1-7中任一项的化合物或其药学可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药，或者权利要求8的药物组合物。
  10. 权利要求1-7中任一项的化合物或其药学可接受的盐、立体异构体、互变异构体、多晶型物、溶剂合物、N-氧化物、同位素标记的化合物、代谢物或前药、权利要求8的药物组合物或权利要求9的药物制剂在制备用于预防或治疗RORγ相关疾病的药物中的用途，其中所述药物优选为通过口服、静脉内、动脉内、皮下、腹膜内、肌内或经皮途径给药的药物，其中所述RORγ相关疾病或病症选自肿瘤或癌症，例如非霍奇金淋巴瘤、弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、滑膜肉瘤、乳腺癌、宫颈癌、结肠癌、肺癌、口腔癌、脑癌、胃癌、肝癌、直肠癌、胰腺癌、皮肤癌、前列腺癌、骨癌、肾癌、卵巢癌、膀胱癌、输卵管肿瘤、腹膜肿瘤、黑色素瘤、实体瘤、神经胶质瘤、神经胶母细胞瘤、乳突状恶性瘤、头颈部肿瘤、白血病、淋巴瘤或骨髓瘤。
  11. 根据权利要求10所述的用途，其中所述药物还包含其他抗肿瘤剂。
  12. 制备式(II-A)的化合物的方法，所述方法包括以下步骤：
    Figure PCTCN2019094579-appb-100010
    其中，X表示离去基团，所述的离去基团包括但不限于卤素原子、甲磺酰基氧基、对甲基苯磺酰基氧基等，R 1、R 2、R 3、R a、R b、环A 1、环A 2、m、n如权利要求2中所定义；
    (1)使化合物IN-A-1与化合物IN-A-2反应以得到化合物IN-A-3；
    (2)使化合物IN-A-3与化合物IN-A-4进行关环反应以得到化合物IN-A-5；或者当化合物IN-A-5中的R a与R b均为甲基时，也可以使化合物IN-A-3与2-甲氧基丙烯进行关环反应以得到化合物IN-A-5；
    (3)使化合物IN-A-5与化合物IN-A-6反应以得到化合物IN-A-7；
    (4)使化合物IN-A-7与化合物IN-A-8反应以得到式(II-A)的化合物；
    或者
    制备式II-B的化合物的方法，所述方法包括以下步骤：
    Figure PCTCN2019094579-appb-100011
    其中，X表示离去基团，所述的离去基团包括但不限于卤素原子、甲磺酰基氧基、对甲基苯磺酰基氧基等，R 1、R 2、R 3、R a、R b、环A 1、环A 2、m、n如权利要求2中所定义；
    (1).使化合物IN-B-1与化合物IN-B-2反应以得到化合物IN-B-3；
    (2).使化合物IN-B-3还原反应以得到化合物IN-B-4；
    (3).使化合物IN-B-4与化合物IN-A-8反应以得到化合物IN-B-5；
    (4).使化合物IN-B-5与化合物IN-A-6反应以得到化合物IN-B-6；
    (5).使化合物IN-B-6与化合物IN-B-7反应以得到式(II-B)的化合物。
PCT/CN2019/094579 2018-07-13 2019-07-03 苯并二氮杂环类化合物、其制备方法及用途 WO2020011086A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980032188.9A CN112119065B (zh) 2018-07-13 2019-07-03 苯并二氮杂环类化合物、其制备方法及用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810769456 2018-07-13
CN201810769456.2 2018-07-13
CN201910022463 2019-01-10
CN201910022463.0 2019-01-10

Publications (1)

Publication Number Publication Date
WO2020011086A1 true WO2020011086A1 (zh) 2020-01-16

Family

ID=69142159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/094579 WO2020011086A1 (zh) 2018-07-13 2019-07-03 苯并二氮杂环类化合物、其制备方法及用途

Country Status (2)

Country Link
CN (1) CN112119065B (zh)
WO (1) WO2020011086A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705501A (zh) * 2013-09-09 2016-06-22 百时美施贵宝公司 RORγ调节剂
WO2016179343A1 (en) * 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107001358A (zh) * 2014-10-29 2017-08-01 东亚St株式会社 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物
CN107980042A (zh) * 2015-06-11 2018-05-01 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CN105085504B (zh) * 2014-04-16 2018-03-30 北京大学 4‑取代苯磺酰胺衍生物及其制备方法和应用
AU2016319638B2 (en) * 2015-09-09 2021-02-11 Jubilant Biosys Limited Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors
WO2017213210A1 (ja) * 2016-06-10 2017-12-14 武田薬品工業株式会社 複素環化合物
CN108689942B (zh) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705501A (zh) * 2013-09-09 2016-06-22 百时美施贵宝公司 RORγ调节剂
CN107001358A (zh) * 2014-10-29 2017-08-01 东亚St株式会社 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物
WO2016179343A1 (en) * 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107980042A (zh) * 2015-06-11 2018-05-01 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物

Also Published As

Publication number Publication date
CN112119065A (zh) 2020-12-22
CN112119065B (zh) 2024-01-23

Similar Documents

Publication Publication Date Title
CN111647000B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
TWI662026B (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
JP2021528469A (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
JP2016519674A (ja) 過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
TW201625533A (zh) Ｋｃｎｑ ２至５通道活化劑
WO2023098439A1 (zh) 一种吡唑衍生物，其制备方法和在药学上的应用
WO2020233641A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2015139619A1 (zh) 作为RORγ调节剂的化合物
WO2019228404A1 (zh) 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
CN108863850B (zh) 联芳基类化合物及其制备方法和用途
TW201623257A (zh) 藥理活性之喹唑啉二酮衍生物
CN112851557B (zh) 磺基取代的联芳基类化合物或其盐及其制备方法和用途
WO2020011220A1 (zh) 杂芳基类衍生物、其制备方法及其在医药上的应用
WO2022166860A1 (zh) Pim激酶抑制剂
WO2018145653A1 (zh) 联芳基类化合物及其制备方法和用途
CN109071550B (zh) 具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
JP2986920B2 (ja) 治療に有用なキノキサリン誘導体
WO2020200160A1 (zh) 一种含喹啉基化合物、药物组合物以及其用途
WO2020082921A1 (zh) 一种氮杂芳基酰胺衍生物及其制备方法和应用
WO2020011086A1 (zh) 苯并二氮杂环类化合物、其制备方法及用途
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
WO2021227906A1 (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
WO2020199945A1 (zh) 一类邻位羰基氨基取代苯衍生物、其制备方法和用途
WO2017219935A1 (zh) 联芳基脲类衍生物或其盐及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19833881

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19833881

Country of ref document: EP

Kind code of ref document: A1